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Abstract 
Jones W. Bryan, Jr. Calcium Diluents as Matrix Forming Agents 
in sustained Release Dosage Forms. (Under the direction 
of J. DAVID McCALLISTER). 
The purpose of this research was to evaluate the effect 
of the poorly soluble diluents; calcium sulfate dihydrate, 
dibasic calcium phosphate dihydrate, and tribasic calcium 
phosphate on medicament release from solid dosage forms. 
Initial findings led to an investigation of the use of these 
diluents as matrix forming agents in the formulation of 
sustained release solid dosage forms. An existing single 
station tablet press was instrumented with a transducer strain 
gauge apparatus to monitor compression force applied during 
tablet manufacture. An automated dissolution system was used 
to determine medicament release from the dosage forms under 
investigation. 
These three diluents when directly compressed with drug 
had shown matrix forming abilities in media of pH 4.0 to 7.5. 
However, they do not exhibit these same abilities in O.lN HCl. 
The addition of Carbopol 934P (1-5%) provided a gel-like 
protective barrier in O.lN HCl and acacia assisted in 
maintaining the matrix structure in this acidic environment. 
v 
In addition, medicament release appeared nearly constant over 
eight to ten hours. The tablets were manufactured by weighing 
the excipients, screening to eliminate agglomerates, blending, 
and compressing. 
Acetaminophen was chosen as model drug due to its 
relatively pH independent solubility profile over the range of 
interest. However, the system also showed the ability to 
sustain the release of theophylline and chlorpheniramine 
maleate. 
Results indicate promise for the use of these calcium 
diluents as matrix forming agents in the formulation of 
sustained release solid dosage forms. Medicament release can 
be controlled by adjustment of formulation variables and this 
simple process appears unaffected by several processing 
variables. The simplicity, novelty, and applicability of this 
method of achieving sustained release of medicament from solid 
dosage forms warrants additional investigation of its use in 
the formulation of pharmaceutical products. 
vi 
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Chapter I. Introduction 
The development of sustained release solid dosage forms 
for the delivery of existing drug entities has been the focus 
of intense investigation in the pharmaceutical industry in an 
effort to improve the efficiency of drug therapy. This 
approach not only improves drug therapy, but it can also 
prolong the patent rights to the particular drug entity. A 
number of approaches have been taken in the formulation of 
solid dosage forms for sustained release. Many of these are 
technologically complicated, financially prohibitive, and 
scientifically not reproducible (Welling). The directly 
compressible and practically insoluble characteristics of the 
pharmaceutical diluents; calcium sulfate dihydrate, dibasic 
calcium phosphate dihydrate, and tribasic calcium phosphate 
make them excellent candidates for incorporation into 
sustained release dosage forms. The use of these diluents as 
matrix forming agents in sustained release dosage forms is the 
focus of this doctoral research project. 
When these calcium diluents are directly compressed with 
the model drug acetaminophen, sustained release of drug occurs 
via a matrix type system in media of pH 4.0 to 7.5 over an 
eight hour period. However, these diluents are more soluble 
at pH 1.1 and the dosage forms slowly dissolve releasing drug 
at a much faster rate. 
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In this study, acetaminophen USP powder was used as a 
model drug for several reasons. Acetaminophen possesses a 
solubility profile relatively independent of pH over the range 
which corresponds to that of the human gastrointestinal tract. 
It is easily assayed via ultraviolet spectrophotometric means, 
and is directly compressible making it a physically acceptable 
candidate for formulation in a sustained release vehicle. 
Pharmaceutical grade Carbopol 934P is a carboxy-
polymethylene polymer. In the presence of acidic media, 
Carbopol 934P gels to form a physically stable mass. When 
blended with the aforementioned calcium diluents and 
compressed, dosage forms result which exist as a loosely 
defined mass in the presence of O.IN Hel. 
Acacia NF is a naturally occurring gum often employed as 
a binder in the formulation of solid dosage forms at levels 
normally ranging from 2 to 10% of total tablet weight. When 
formulated with the cited calcium diluents, acacia serves to 
impart a cohesive character to the blend which makes it more 
amenable to the direct compression process. It also supports 
the tablet infrastructure formed by the directly compressible .. 
calcium diluent. 
It appears feasible that if Carbopol 934P and acacia 
could simultaneously impart their physical characteristics on 
3 
a blend of calcium diluent and drug a sustained release matrix 
type drug delivery system could result. The development of 
this type of vehicle involves formulation design, process 
optimization, and thorough performance evaluation. Design of 
the formulation involved the following: i) the use of calcium 
diluents which exhibit matrix sustained release properties in 
the pH range of 4.0 to 8.0, ii) Carbopol 934P as a gelling 
agent to provide a gel protective barrier in the presence of 
O.lN HCl, and iii) acacia, a natural gum to assist in 
preservation of the matrix structure throughout the release 
process. Studies were conducted to evaluate the in vitro 
performance of the sustained release vehicle via an automated 
sampling apparatus on-line with an ultraviolet 
spectrophotometer. 
A Manesty F3 Single Punch Tablet Press was modified and 
instrumented with a transducer strain gauge to monitor 
compression force employed in the manufacture of experimental 
tablets. The effects of several formulation and production 
variables were evaluated for their effects on medicament 
release. 
. . 
The goal of this research was to investigate the matrix 
forming capabilities of the three calcium diluents and their 
possible use in the formulation of sustained release solid 
dosage forms. A simple formulation and production process 
4 
could possibly result in addition to an understanding of the 
parameters contributing to the performance of this vehicle. 
The evaluation of the ability of this vehicle to sustain the 
release of several existing drugs including theophylline and 
chlorpheniramine maleate would further validate its 
application as a viable approach to drug delivery. The 
ultimate goal of this research project is to evaluate and 
characterize an alternative approach to the formulation of 
sustained release solid dosage forms. 
Chapter II. Background 
At least 90% of all drugs intended to produce systemic 
effects are administered via oral solid dosage forms (Theory 
and Practice). There are several advantages to the 
administration of these types of dosage forms. Most 
importantly, a large percentage of drugs on the pharmaceutical 
market are amenable to the tableting process via direct 
compression or wet granulation procedures. In addition, 
relatively large quantities of drug can be incorporated into 
either tablet or capsule making high dose drugs viable 
candidates for delivery from these systems. Solid dosage 
forms are also chemically and physically stable relative to 
other pharmaceutical dosage forms namely those of the liquid 
and semisolid nature. From a pharmaceutical development 
perspective other advantages include dose precision, low 
content variability, low cost of production, light and compact 
nature for shipping, inexpensive to package, simple 
application of product identification material, and the ease 
with which the product can be administered to the patient. 
They also lend themselves to certain special-release profile 
products such as enteric or delayed-release products. Due to 
these advantages, delivery of drugs via solid dosage forms is 
and will continue to be the primary route by which therapeutic 
agents will be administered (Gardner). 
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The overwhelming popularity of the solid dosage form and 
the escalating costs associated with the development of New 
Chemical Entities (NCE) are two reasons why many resources are 
being invested to improve the performance and delivery of 
existing drugs. The majority of tablets and capsules are 
designed to release their entire drug content upon immediate 
contact with the aqueous media of the gastrointestinal tract, 
hence exposing the drug for systemic absorption and 
pharmacological 'action as quickly as possible (Shah). For 
many acute conditions, this type of drug delivery is 
satisfactory but there are problems which may arise with this 
method of drug delivery. 
When the drug candidate is exposed to the media of the 
gastrointestinal tract it is dissolved and becomes available 
for absorption into the systemic circulation. As drug is 
systemically absorbed its concentration in the bloodstream 
will reach peak levels sometimes approaching toxic levels 
(Baker). Even before peak blood levels are obtained the body 
will begin to eliminate the drug via filtration, degradation, 
and/or harboring of the drug in bodily tissue. In order for 
these levels to remain sufficiently high to elicit a desired 
pharmacological effect, enough drug must be present initially 
to maintain this response and to compensate for its continuous 
removal from the systemic circulation. Each drug possesses 
its own elimination kinetics and will exhibit a different time 
course profile in the body. 
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An extended duration of 
pharmacological action is desired in most cases (Lipowski). 
There are two common approaches which can be utilized with 
immediate release dosage forms to achieve this extended 
duration of pharmacological action. 
The initial dose of drug administered can be increased 
to provide a higher initial concentration of drug in the 
blood which results in a longer duration of pharmacological 
action. However, this scenario heightens a concern for the 
occurrence of toxic side effects precipitated by these higher 
levels. For drug candidates with narrow therapeutic windows, 
in which the ratio of the maximally safe blood concentration 
to the minimally effective blood level is small, this is a 
major concern (Baker). 
Desired levels can also be maintained through repetitive 
dosing which is the most commonly used method with orally 
administered immediate release solid dosage forms. In this 
case the dosage form is administered to the patient usually 
every 4 - 6 hours. As the level of drug in the blood begins 
to decrease and approach the minimum effective concentration 
the administration of a subsequent or maintenance dose will 
serve to compensate for this loss and to maintain the blood 
drug levels within the desired therapeutic window. Although 
commonly employed, this approach increases the role of the 
8 
patient who is usually responsible for admiministering the 
dosage form. If the dosage form is administered too 
frequently or as a multiple dose, blood levels may rise to 
heights that are threatening to the physical well being of the 
patient. Conversely, if the patient fails to administer the 
dose on time the blood level will fall below its minimum 
effective concentration yielding a period of diminished 
pharmacological effect (Chien). 
An alternative approach which has been successfully 
used to prolong blood drug levels within the therapeutic 
window is that of the delivery of medicament via sustained 
release mechanisms. 
2.1. sustained Release 
sustained drug delivery involves the release of the drug 
candidate into the aqueous media of the gastrointestinal tract 
at a controlled rate, hence a limitation of the rate at which 
the drug can be absorbed into the systemic circulation. A goal 
for systemic drug administration is to achieve a 
therapeutically effective blood or tissue level for an 
extended period of time without producing toxic side effects 
(Lordi) . Sustained drug delivery addresses this goal by 
controlling the appearance of drug in the systemic 
9 
circulation. 
Some 32 different names exist which refer to or are 
closely analogous to sustained release solid dosage forms 
(Madan) . sustained action, controlled release, prolonged 
action, extended action, timed release, and prolonged release 
are just a few of these terms. Sustained release will be used 
here to specifically refer to drug delivery systems utilized 
to continuously release drug over an extended period of time. 
2.1.1. Advantages 
One goal of sustained release products is to deliver 
medication to the patient in a predictable and reproducible 
fashion (Chien). Since a sustained release product functions 
to maintain the blood drug levels for an extended period of 
time, the frequency of administration is reduced relative to 
that required with multiple dosing via an immediate release 
dosage form (Silber). This less frequent administration 
decreases the role of the patient in drug therapy and 
consequently should maximize patient compliance. Decreasing 
the frequency of administration is obviously important when 
one considers that patient non-compliance with recommended 
therapy occurs in 25% to over 50% of all out-patients 
(Blackwell). 
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Dosing of patients in the conventional manner of 
immediate release mechanisms creates blood level profiles 
which exhibit concentration peaks soon after administration 
followed by minimum blood levels just prior to the 
administration of the maintenance dose (Chien). The ratio of 
these peak to trough plasma concentrations has been quantified 
by the Dosage Form Index (01) which is defined as the ratio of 
the maximum to the minimum concentration achieved during a 
dosage cycle (Theeuwes). This type of profile exhibits an 
oscillating character. sustained release products function to 
eliminate these peaks and valleys by maintaining more of a 
steady state concentration through continuous drug release. 
This decreases the incidence and severity of side effects 
normally associated with peak blood levels (Levy). A well-
designed controlled release system should release its drug 
content in a fashion which will produce blood levels 
exhibiting a DI which is as small as possible and falls within 
the desired therapeutic window. Essentially, the use of 
sustained release drug delivery systems serves to provide a 
safer and more reliable mode of therapy for the patient 
(Longer). 
2.1.2. Disadvantages 
The possible disadvantages that may be associated with 
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the design and ultimate administration of any dosage form 
must be thoroughly evaluated. The administration of 
sustained release products does have the potential to create 
problems. These problems may justify the choice of 
another route of therapy in certain but not all cases. 
Probably the most common concern with sustained release 
medications is that the abrupt termination of drug therapy 
is not possible. Once the dosage form has been ingested 
there is no convenient means of terminating the release of 
the remaining drug to the patient (Lordi). An example would 
be a patient who experiences adverse reactions to the 
medication and the lack of ability to remove the dosage form 
from the patient in an attempt to arrest the episode. This is 
especially a concern with sustained release dosage forms which 
traditionally contain 3 to 4 times the dose of conventional 
immediate release dosage forms. 
The amount of drug present in the sustained release 
dosage form is a fixed quantity. There is little or no 
flexibility afforded the physician in making dosage 
adjustments. Hence, patient to patient response variation 
cannot be easily addressed by the physician. 
Due to processing and materials man~~ sustained release 
"'r./ 
\,~ ........ ..,,- ..-". >' -~., ,.,.' 
delivery systems that are currently on the market or under 
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development may be cost prohibitive (Kydonieus). Specialized 
equipment, highly trained personnel, and custom excipients are 
just a few of the costly items associated with the formulation 
and production of these products. A goal of this research is 
to overcome these obstacles through the manufacture of 
reliable sustained release solid dosage forms utilizing 
existing inexpensive pharmaceutical excipients and simple 
production procedures. 
2.1.3. Approaches 
Approaches to the delivery of medicament via oral 
sustained release solid dosage forms which have been 
successfully implemented or proposed for future development 
tend to fall into three general categories: modification of 
the drug molecule, dosage form design, or product 
formulation. 
2.1.3.1. Molecular Modification 
Modification of the drug molecule involves the 
complexation of the drug molecule, adsorption of the 
molecule onto a suitable carrier, or the synthesis of a 
prodrug. All of these approaches rely heavily on in vivo 
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conditions for the successful release of the active drug 
moiety from its complex, dissociation from the carrier 
molecule, or conversion from a prodrug state to its active 
parent molecular form (Kwan). Some examples of drugs from 
which prodrugs have been synthesized include isoproterenol, 
isoniazid, and penicillin (Sinkula). Due to patient"!" to""" 
patient physiological variability, all of these methods appear 
susceptible to unpredictable release characteristics and may 
be classified as unfavorable routes of sustained drug 
delivery. Yet another concern with these approaches is the 
complication of the production process due to the additional 
synthetic procedures that have been introduced. Synthetic 
reproducibility, time, and material costs may all be new 
concerns associated with these methods. Modification of an 
existing drug substance may result in the formation of a new 
chemical entity (NeE) which warrants studies to investigate 
its safety and efficacy. 
2.1.3.2. Dosage Form Design 
sustained release of medicament from solid dosage forms 
via specialized dosage form design is an approach that has 
received much attention in the last decade and will continue 
to be a target for research and development scientists in the 
future. This is a consequence of the simultaneous maturation 
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of various factors, including the prohibitive costs of 
developing new drug entities, the expiration of existing 
patents, and the discovery of novel polymer systems and 
devices suitable for controlled delivery of oral dosage forms 
(Welling). 
There are numerous dosage form designs that have been 
implemented or are under investigation for sustained drug 
delivery from solid dosage forms. A few examples include 
intragastric floating devices, inflatable devices, osmotically 
controlled devices, hydrodynamic pressure controlled systems, 
membrane controlled devices, mul tilaminate forms, polymer 
coated systems, and bioadhesive devices (Banakar). Although 
technologically impressive this list of innovative delivery 
systems contains endless possibilities for mechanical failure, 
cost prohibition, and reproducibility downfalls. 
For example, the floating drug delivery (U.S. Patent No. 
4,167,558) device appears to be a technological advancement 
for prolonging dosage form dwell time in the gastric region 
(Banakar), but the device relies heavily on its proper 
mechanistic function and the nature of the gastric 
environment. These devices are designed to form a water-
impermeable colloid gel barrier on their surface upon contact 
with gastric fluids thereby maintaining a bulk density of < 1 
and allowing the dosage form to remain buoyant in the stomach 
until the entire loading dose is released. 
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Other similar 
devices such as the gastro-inflatable drug delivery device 
functions via an inflatable chamber which contains a liquid 
which gasifies at room temperature and imparts a buoyant 
nature to the dosage form. The inflatable chamber also 
contains a bioerodible polymer filament which is dissolved 
gradually by gastric fluid. Eventually it causes the chamber 
to collapse and result~· in ejection of the device from the 
stomach. 
Other devices include the osmotic pressure-controlled 
drug delivery system (U.S. Patent 4,036,227, G.B. Patent 
1, 551,898) • They function by virtue of a semipermeable 
coating which allows entry of gastric fluid to a drug filled 
reservoir from which release occurs through a laser drilled 
orifice along an osmotic gradient. 
The membrane diffusion-controlled drug delivery systems 
(U.S. Patent 7,313,696, B.E. Patent 814,491) appear to be more 
mechanistically and developmentally feasible. This class of 
designs include the microporous membrane-coated tablets which 
constitute a compressed tablet coated with a gastric .. , fluidp,~" 
resistant polymer impregnated with a water-soluble inorganic 
sUbstance. Upon initial contact with the contents of the 
gastrointestinal tract the inorganic sUbstance dissolves and 
creates a porous membrane through which medicament can be 
16 
released at a controlled rate. 
All of these approaches and related techniques are 
technologically impressive but the question of their 
practicality and feasibility must be raised when one considers 
the dependence of their performance on mechanistic precision, 
the characteristics of the patient's gastric environment,and 
large scale production reproducibility. In addition, 
production costs of such devices is a concern in the 
pharmaceutical industry. 
2.1.3.3. Formulation Approach 
Probably the least complicated approach to the 
manufacture of sustained release dosage forms is that of the 
formulation of drug with retardant material in a directly 
compressible manner. The retardant material and additives are 
blended with the drug and directly compressed into a solid 
dosage form (Lordi). The retardant material forms a matrix 
which either maintains its structure or slowly erodes in the 
aqueous media of the gastrointestinal tract and releases drug 
in a sustained fashion. Parameters which affect the rate of 
drug release from these matrix systems will be discussed in 
detail in a later section. 
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Pharmaceutically acceptable excipients which possess 
these matrix forming capabilities fall into three categories 
based on their in vitro characteristics. The first of these 
classifications is the hydrophilic matrix forming materials 
including methylcellulose, hydroxyethylcellulose, 
hydroxypropylmethylcellulose, sodium carboxymethylcellulose, 
and acrylic acid copolymer (carboxypolymethylene). 
These hydrophilic materials form gels in situ. A 
sustained release mechanism exists as a result of the function 
of a slightly water-permeable polymer gel barrier on the outer 
surface of the tablet. This barrier permits only slow 
diffusion of fluids into and through the interior of the 
tablet. Occurring simultaneously with this diffusion process 
is an erosion of the gel layer of the tablet caused by 
external agitation. As the gel layer deteriorates it carries 
some of the admixed medicament after which new gelled material 
is exposed and the process continues. Thus the tablet is 
slowly disintegrated which causes slow release of drug, 
generally at a substantially constant rate. The rate of 
release of drug from these polymeric systems is dependent on 
the polymer selected, and the drug: polymer ratio of the 
formulation (U.S. Patent 3,065,143 and U.S. Patent 3,074,852). 
Incorporation of other excipients such as lactose can be used 
to adjust the release rates of the drug candidate as in the 
case of low-milligram-potency formulations (Salomon). 
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One approach to employing these hydrophylic gel-forming 
materials in the formulation of sustained release solid dosage 
forms has been described previously (U.S. Patent No. 
3,330,729). The patent claims that the admixture of at least 
5% of cross-linked acrylic acid polymer with at least one 
inexpensive pharmaceutically acceptable calcium or magnesium 
compound can obtain the same degree of sustained release as 
that obtained with a greater amount of polymer and none of the 
basic compound. A comparison of tablets containing the same 
amount of polymer and medicament indicates that those 
additionally containing the basic diluent showed considerably 
slower release than tablets lacking such material. The basic 
diluents stated as suitable in the patent are magnesium oxide, 
magnesium hydroxide, and calcium hydroxide. A similar, yet 
novel approach to the use of hydrophilic gelling materials in 
combination with basic diluents in the formulation of 
sustained release solid dosage forms is the focus of this 
doctoral research project. 
A second group of matrix forming materials include? 
insoluble, erodible materials such as Carnauba wax, castor 
wax, and triglycerides which function to release their drug 
content through both pore diffusion and erosion. These 
materials are used in combination with stearyl alcohol, 
stearic acid, hydrogenated castor oil, and propylene glycol 
monostearate to govern release of medicament from these matrix 
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formulations. 
These formulations are processed via several methods in 
preparation for tableting. Solvent evaporation technique in 
which a solution or dispersion of the drug and additives is 
incorporated in the molten wax phase is one common approach. 
After evaporating the solvent the dry blend is-granulated and 
compressed. A second approach is the dry blending of drug 
with retardant material and additives followed by slugging, 
granulation, and compression of the formulation into its solid 
form. The fusion technique in which the wax material is 
heated to slightly above its melting point and drug is 
incorporated is a third approach. The molten mass is spray-
dried, solidified and milled, solidified and flaked, or poured 
on a cold rotating drum to form a continuous sheet which ~~e 
then milled and screened to form a granulation (Theory and 
Practice). One drawback to the use of these retardant waxes 
is that total release of drug is not possible. This occurs by 
virtue of a portion of the drug content being totally occluded 
or coated by the waxy material and hence retained in the 
tablet core (D'Arcy). 
The third group of matrix forming materials include 
insoluble, inert materials such as polyethylene, polyvinyl 
chloride, methyl acrylate-methacrylate copolymer, and 
ethylcellulose. Formulations incorporating these materials 
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are designed to be directly compressed with drug and remain 
intact after entering the gastrointestinal tract. Release of 
drug from these tablets is controlled by the rate of 
penetration of the aqueous media of the gastrointestinal tract 
into the tablet matrix and subsequent diffusion of the 
dissolved drug from the matrix structure. This type of 
insoluble matrix sustained release system is the focus of this 
doctoral research project and will be discussed in greater 
detail in subsequent sections. 
2.1.4. Candidates 
Not all therapeutic agents are viable sustained release 
candidates and therefore must be evaluated on an individual 
basis from a physicochemical perspective to determine the 
practicality and feasibility of their delivery in this manner. 
When evaluating candidates for sustained delivery there are 
several parameters that must be considered. The most common 
concerns for a sustained release candidate are its 
physicochemical properties, its biological half-life, required 
therapeutic dose, therapeutic index, and region of 
gastrointestinal absorption (Shah). 
Drugs with long biological half-lives are not good 
candidates for sustained release. with the major goal of 
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sustained drug delivery being the prolongation of the 
existence of therapeutically effective levels of drug in the 
bloodstream a drug with a long biological half-life would have 
already accomplished such a goal. If elimination of the drug 
is slow and its therapeutic window is not prohibitively 
narrow, then blood levels will be maintained for a lengthy 
duration. 
In contrast, drugs with very short biological half-lives 
have the opposite problem. If elimination of drug from the 
bloodstream is rapid, then blood levels will fall from the 
therapeutic window shortly after introduction into the 
systemic circulation. Introduction of a higher initial dose 
to compensate for this rapid loss could heighten the risk of 
the occurrence of adverse side effects. 
sustained release solid dosage forms normally contain 
three to four times the amount of drug contained in an 
immediate release dosage form of the same drug. Therefore, 
drugs that require a high dose (~ 300 mg) would present a 
dosage form size problem. A sustained release version would 
contain 900 to 1200 mg of the drug. Patients traditionally 
have difficulty ingesting solid dosage forms > 800 mg in 
weight. 
Yet another concern is the area of the gastrointestinal 
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tract over which the therapeutic agent is absorbed. It is 
logical that if the release of drug is going to be sustained 
over the entire length of the gastrointestinal tract then it 
must also possess the ability to be systemically absorbed over 
that same region. For example, a drug which can only be 
absorbed in the stomach is not a viable candidate for 
sustained release through the intestine. In this particular 
case, blood levels would increase initially due to release in 
the stomach. The drug remaining in the dosage form would be 
released in the intestine but will elicit no additional 
pharmacological action due its lack of systemic absorption. 
There are many other less obvious concerns associated 
with the evaluation of the incorporation of a drug substance 
into any type of delivery system. Some of these include the 
amenability of the drug to the particular production 
procedure, the physical and chemical stability of the 
candidate in the vehicle, the costs of the excipients involved 
in the formulation, and the marketability of the finished 
product. These are just a few of the concerns involved in the 
planning, development, and ul timate success of any 
pharmaceutical product. 
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2.2. Calcium Diluents 
Calcium sulfate dihydrate, dibasic calcium phosphate 
dihydrate, and tribasic calcium phosphate are three salt forms 
that have been used in the pharmaceutical industry as tablet 
and/or capsule diluents (Handbook). In recent years their use 
in this capacity has decreased in favor of the more soluble 
diluents such as lactose. The insoluble nature of these three 
calcium diluents led to the initial investigation of their 
effect on release of medicament from solid dosage forms and 
ultimately to the doctoral research project. 
2.2.1. Calcium Sulfate Dihydrate 
Calcium sulfate is known as calcium sulfate dihydrate, 
gypsum, alabaster, terra alba, satinite, satin spar, light 
spar, mineral white, native calcium sulfate, precipitated 
calcium sulfate, and plaster of Paris. It is supplied 
commercially by numerous chemical companies registered in the 
united states and the united Kingdom ("Calcium Sulfate"). 
Calcium sulfate is functionally categorized as a tablet 
and/or capsule diluent and is described as a white to 
yellowish-white powder, odorless, and tasteless. Its directly 
compressible character and ability to form a durable matrix 
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structure on compression are two vital properties in the 
development of this research project. 
The stability of calcium sulfate lends itself to use in 
the pharmaceutical industry from a storage and formulation 
standpoint. The diluent is chemically stable although it may 
absorb moisture and cake on standing which necessitates 
storage in a well-closed moisture resistant container. These 
types of storage conditions are normal practice in the 
pharmaceutical industry and therefore should not create any 
undue problems in its use (Handbook). 
From a formulation perspective, calcium sulfate dihydrate 
possesses no reported incompatibilities in the solid state 
under dry conditions and should create a relatively stable 
environment for a drug moiety when incorporated in a solid 
dosage form. However, in the presence of moisture the ionic 
calcium cation may be incompatible and form complexes with 
amines, amino acids, peptides, and proteins (Handbook). 
Due to the limited gastrointestinal absorption of calcium 
from its salts, calcium sulfate will not induce hypercalcemia 
even when massive dosages are swallowed (Handbook). 
Another consideration in the use of calcium sulfate as a 
diluent in the formulation of solid dosage forms is its 
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relatively reasonable cost and the ease with which it can be 
obtained from a number of chemical supply companies. 
2.2.2. Dibasic Calcium Phosphate Dihydrate 
Dibasic calcium phosphate is known as calcium hydrogen 
orthophosphate and secondary calcium phosphate. It is 
supplied for pharmaceutical application as Ditab and 
EmcomPress. The powder forms of dibasic calcium phosphate are 
available from numerous chemical companies in the united 
states and the united Kingdom (nDibasic Calcium Phosphate"). 
Dibasic calcium phosphate dihydrate is functionally 
categorized as a tablet and/or capsule diluent for use in the 
pharmaceutical industry and is available in direct compression 
grades. It is described as white, odorless, and tasteless 
powder or. crystalline solid. It is soluble in dilute 
hydrochloric acid and nitric acids, very slightly soluble in 
water, and slightly soluble in dilute acetic acid. This 
solubility profile led to the initial investigation of the 
effect of this diluent on the release of medicament from a 
solid dosage form. 
Dibasic calcium phosphate is stable when stored in a 
closed container in a cool, dry place and therefore is 
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amenable to storage for extended periods of time under normal 
pharmaceutical conditions (Handbook). 
From a formulation perspective, dibasic calcium phosphate 
may be incompatible with some acids and may interfere with the 
absorption of tetracyclines. There are no other documented 
incompatibilities in its use (Handbook). 
There is no documentation of illness resulting from 
exposure to dibasic calcium phosphate in industrial settings. 
Ingestion of large quantities may result in symptoms of 
gastro-intestinal irritation and inhalation of high airborne 
concentrations may result in non-specific irritation of the 
upper respiratory tract. These remotely possible safety 
hazards are easily avoidable when Good Manufacturing Practices 
for handling pharmaceutical excipients are observed 
(Handbook) . 
Even though direct compression grades of dibasic calcium 
phosphate such as EmcomPress (Mendell) exist, the powder forms 
of these diluents are directly compressible. In this research 
project dibasic calcium phosphate dihydrate (Amend) was 
incorporated as a diluent in a directly 
formulation employing compression forces of 
pounds. 
compressible 
3500 to 6000 
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Dibasic calcium phosphate dihydrate is also a relatively 
inexpensive pharmaceutical excipient and is readily obtained 
from numerous chemical supply companies. 
2.2.3. Tribasic Calcium Phosphate 
Tribasic calcium phosphate is known as calcium hydroxide 
phosphate, tricalcium orthophosphate, tertiary calcium 
phosphate, calcigenol simple, calcium orthophosphate, and 
precipitated calcium phosphate. It is supplied for 
pharmaceutical use by numerous chemical supply companies in 
the united states and the united Kingdom (Handbook). 
Tribasic calcium phosphate is functionally categorized as 
a filler for tablets and capsules and as an anti-caking agent. 
It is described as a white, odorless, tasteless powder which 
is stable in air. It is soluble in dilute mineral acids, only 
slightly soluble in water, and insoluble in alcohol. This 
type of solubility profile is a key factor under investigation 
in this research proj ect. When directly compressed under 
forces of 3500 to 6000 pounds this diluent forms a strong 
solid mass. 
Tribasic calcium phosphate is a stable compound and is 
easily stored without caking problems. In formulation it may 
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influence the absorption of vitamin 0 and may form sparingly 
soluble phosphate with hormones. It will also form calcium 
complexes with tetracycline (Handbook). 
There are no documented cases of illness resulting from 
industrial exposure to tribasic calcium phosphate. Inhalation 
of excessive quantities may result in deposition of tribasic 
calcium phosphate crystals in bodily tissues. Inflammation of 
these tissues would be the resulting symptom. No precautions 
are specified in the handling of this excipient (Handbook). 
Tribasic calcium phosphate is relatively inexpensive and is 
readily available from chemical supply companies. 
2.3. Excipients 
Excipients incorporated in directly compressed solid 
dosage forms must yield a product that is strong, durable, 
pharmaceutically elegant, chemically stable in the presence of 
drug, and able to release its drug content for absorption in 
the gastrointestinal tract. 
Most solid dosage forms achieve this release through 
disintegration followed by dissolution of the medicament into 
the aqueous environment of the gastrointestinal tract. 
Following the passage of drug into solution it is absorbed 
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into the systemic circulation for distribution and ultimate 
exertion of its pharmacological activity. 
The function of sustained release solid dosage forms is 
to release medicament over an extended period of time (8 - 12 
hrs. ). The dosage form must therefore remain intact or slowly 
erode for the duration of the desired release period for the 
purpose of providing a reservoir from which the drug can be 
continuously released. Materials utilized in the formulation 
of such sustained release vehicles must be practically 
insoluble in the aqueous media of the gastrointestinal tract. 
Calcium sulfate dihydrate, dibasic calcium phosphate 
dihydrate, and tribasic calcium phosphate are all practically 
insoluble in a pH range of 4.0 to 8.0 corresponding to that of 
the human intestine but are somewhat more soluble in a more 
acidic pH of 1. 0 to 2. 0 which corresponds to that of the 
stomach. These diluents possess the ability to form a matrix 
structure and to deliver medicament at a controlled rate over 
an 8 to 12 hour period in this higher pH range. Conversely, 
they do not exhibit such characteristics in the lower pH 
range. 
If other excipients could be incorporated in this vehicle 
to impart a more acid .... resistant nature or to assist in 
maintaining its matrix structure, they could perhaps be used 
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with these calcium diluents as matrix forming agents for 
sustained release solid dosage forms. 
Several natural gums, synthetic polymers, and tablet 
binders including acacia, xanthan gum, veegum, carbomer, 
cellulose derivatives, and polyvinylpyrrolidone were screened 
for their ability to hold the matrix intact when subjected to 
acidic media. Acacia (Amend) and Carbopol (B.F. Goodrich) 
appeared to yield the most promising results when used in 
combination with the calcium diluents. 
2.3.1. Acacia 
Acacia (gum acacia and gum arabic) is extracted from 
trees of the genus Acacia which grow in the Sudan and Senegal 
region of Africa. It is available commercially from several 
chemical supply companies in both the united States and the 
United Kingdom ("Acacia"). 
Acacia is functionally categorized as a tablet binder, 
suspending and/or viscosity increasing agent, and emulsifying 
and/or solubilizing agent. It is also listed as a protective 
colloid. It is described as white to yellowish-white in 
color, odorless, and bland tasting. It is available as thin 
flakes, spheroidal tears, or in powdered or granular form. 
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Some of its typical properties and specifications are listed 
in the Table below (Handbook). 
Acacia is stable when stored in a tight container in a 
cool, dry place and should be preserved in an air-tight 
container. It is incompatible wi th a number of 
pharmaceutically insignificant materials but has been 
successfully incorporated into solid dosage forms as a binder 
(Handbook) . 
Acacia is recognized as safe for general use as a food 
addi ti ve by the FDA and is free from adverse reactions 
following ingestion. There have been a limited number of 
reports of allergenic reactions in man. There are no existing 
handling precautions (Handbook). 
As a tablet binder acacia is normally employed in a range 
of 1 to 5% of total formulation weight and a warning of 
possible prolonged disintegration times at a level of ~ 5% is 
noted. When acacia (10 to 25%) is employed in combination 
with 1 to 5% Carbopol 934P and calcium diluent an acid 
resistant matrix results which is capable of releasing drug at 
a controlled rate for ten to twelve hours. 
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Properties and Uses of Acacia NF: 
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2.3.2. Carbopol 934P 
Carbopol 934P (carbomer, carbomer 934P, carboxy-
polymethylene, carboxyvinyl polymer, and acrylic polymer) is 
a synthetic, high molecular weight, cross-linked polymer of 
acrylic acid. It is copolymerized with approximately 0.75 to 
2.0 % w/w polyalkylsucrose with an end product containing 56 
to 68 % carboxylic acid groups. It is available commercially 
in a pharmaceutical grade from the B.F. Goodrich Chemical 
Company (Carbomer). 
Carbopol 934P is functionally categorized as a suspending 
and/or viscosity-increasing agent, a thickening agent in 
ointments and creams, and as a tablet binder in sustained 
release dosage forms. It is described as a white, fluffy, 
acidic, and hygroscopic powder with a slight characteristic 
odor. Some of its typical properties and specifications are 
listed in the Table below (Handbook). 
Carbopol 934P is soluble in water, alcohol, and glycerin. 
It can be neutralized by sodium hydroxide, potassium 
hydroxide, sodium bicarbonate, and amino acids. Neutralized 
aqueous gels of carbomer are more viscous between pH 6 and 11 
and this viscosity is considerably reduced if the pH < 3 or > 
12 (Handbook). 
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When stored in an airtight or well-closed container in a 
dry powder form carbomer does not support the growth of molds 
or fungi. It is documented that exposure to light causes 
oxidation which is reflected in a decrease in viscosity. 
Carbomer is incompatible with phenol, cationic polymers, 
strong acids, and high concentrations of electrolytes 
(Handbook) • 
Humans have shown no evidence of primary irritation, 
sensitivity, or allergic reaction to carbomer following 
topical application. However, carbomer can be very irritating 
when in contact with the eye and can be difficult to remove 
due to its gelatinous nature (Handbook). 
In formulation, Carbopol has been incorporated as an 
emulsifying, suspending, and gelling agent at levels ranging 
from 0 • 1 to 2 . 0 ~ o • Carbomer has been used in tablet 
formulations but is most commonly used in liquid and semisolid 
dosage forms. The only grade of this resin which has been 
approved for food use is 934P (Handbook). 
2.3.3. Magnesium stearate 
Magnesium stearate {metallic stearate, magnesium salt, 
and octadecanoic acid} is a commonly used pharmaceutical 















excipient obtainable from numerous chemical supply companies 
in both the united states and the United Kingdom (Magnesium 
stearate) . 
Magnesium stearate is functionally categorized as a 
tablet and/or capsule lubricant and glidant or anti-adherent. 
It is described as a fine, fluffy, white, precipitated or 
milled, impalpable powder of low bulk density with a slight 
but characteristic odor and taste. Due to its lipophilic 
nature it readily adheres to the skin. Some of its typical 
properties and specifications are listed in the Table below 
(Handbook) . 
It is insoluble in water, alcohol, and ether and only 
slightly soluble in hot alcohol and benzene. It is stable 
when stored in a well-closed container in a cool and dry 
place. Incompatibilities exist with acidic substances, 
alkaline substances, and iron salts; mixing with strong 
oxidizing materials should be avoided. Although described as 
a nuisance dust magnesium stearate has been classified as non-
hazardous by the Department of Transportation Regulations 
(Handbook) . 
Magnesium stearate is normally incorporated in tablet and 
capsule formulations at levels between 0.25 and 2.0% but 
levels ~ 1% can create dissolution problems. A level of 0.5% 
38 
was used in all formulations for this research project to aid 
in the tabletting process and prevent sticking in the die 
cavity during ejection (Handbook). 
2.4. Candidates for sustained Release 
Many therapeutic agents have been successfully delivered 
in a sustained fashion via oral solid dosage forms. This 
research project employed three existing drug candidates as 
acceptable representatives in the investigation of a 
prospective~s~e8@iJe sustained release vehicle. 
2.4.1. Acetaminophen 
Acetaminophen (paracetamol; N-acetyl-p-aminophenol) is a 
para-aminophenol derivative which possesses both analgesic and 
antipyretic activity. It is commonly used as an alternative 
to aspirin due to its lesser overall toxicity (Goodman and 
Gilman). Acetaminophen has no antiinflammatory properties. 
Acetaminophen was selected as a model drug in the initial 
phase of the research proj ect due to its pKa ~ 9 . 5 and 
relatively pH independent solubility profile over the pH range 
under investigation (Merck Index). This solubility character 
39 
of the model drug allowed for the control of drug solubility 
as a variable in its release from the dosage form under 
evaluation. 
Although acetaminophen is not a practical sustained 
release candidate due to its high dose restraints its 
application as a model drug allowed for a detailed evaluation 
of the drug delivery system. The successful delivery of 
acetaminophen from this system also provided for a better 
understanding of release based on drugs with similar 
solubility profiles. 
2.4.2. Theophylline 
Theophylline is classified chemically as a xanthine 
derivative and more specifically as a methylxanthine. It is 
an alkaloid which occurs 'in plants widely distributed 
geographically and possesses pharmacological activity which 
stimulates the eNS, acts on the kidney to produce diuresis, 
stimulates cardiac muscle, and relaxes smooth muscle (Goodman 
and Gilman). The latter action constitutes the use of 
theophylline use in the treatment of asthma through 
bronchodilatory effects. 
Theophylline is commonly administered in 100-300 mg 
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quantities three to four times daily via the oral route 
(Patterson) for indications requiring relief of bronchial 
asthma, pulmonary emphysema, chronic bronchitis, etc. 
Theophylline was used in this research project as a 
representative sustained release candidate and to evaluate the 
ability of the vehicle under investigation to sustain its 
release over a ten to twelve hour period. Its relatively poor 
solubility in addition provided an understanding of release 
characteristic of drugs possessing similar solubility 
profiles. Theophylline is weakly acidic and possesses a pKa 
of ~ 8.6. Its solubility is 8.3 mg/ml in water, 12.5 mg/ml in 
ethanol, 11.6 mg/ml in chloroform, and is sparingly soluble in 
ether (Cohen). 
2.4.3. Chlorpheniramine Maleate 
Chlorpheniramine maleate is chemically classified as an 
alkylamine containing a tertiary amino group linked by a three 
carbon chain to two aromatic sUbstituents. It possesses 
pharmacological activity as an histaminic blocking agent which 
blocks selected histamine receptors to the exclusion of 
agonist molecules in a competitive and reversible fashion. 
These pharmacological activities preclude its therapeutic 
application in the symptomatic relief of allergenic responses 
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(Goodman and Gilman). 
Chlorpheniramine maleate is most commonly administered in 
immediate release tablet preparations at 2 to 4 mg every 4 to 
6 hours for adults. sustained release preparations are 
available in 8 to 12 mg doses for administration every 10 to 
12 hours (Facts). 
Employment of chlorpheniramine maleate in this particular 
project allowed for the evaluation of the ability of the 
sustained release vehicle to deliver a common sustained 
release candidate. Its relatively high solubility of ~ 50 
mg/ml in O.IN HCl and low dose also presented an additional 
challenge in controlling its release over an extended period 
of time (Merck). Chlorpheniramine maleate possesses a pKa of 
7.2 and 4.0 with a solubility of ~ 50 mg/ml in O.IN HCl, 180 
mg/ml in O.lN NaOH, and 190 mg/ml in parenteral phosphate 
buffer system. 
2.5. Matrix System Release 
Sustained delivery of several drug candidates has been 
achieved by the blending of drug candidates with matrix 
forming agents and compression into solid dosage forms. Drug 
release from such a system is governed by the chemical and 
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physical properties of the drug itself, the matrix forming 
material, and its constituents included in the formulation. 
Higuchi developed an equation for the release of a drug 
from an ointment base (Higuchi) and later applied it to 
diffusion of solid drugs dispersed in homogenous and granular 
matrix dosage systems. His equation originated with 
consideration of Fick's First Law of Diffusion, 
(1) 
dM dQ Des -------
Sdt dt h 
which may be applied to the case of a drug embedded in a 
polymer matrix. dQ/dt is the rate of drug released per unit 
area of exposed surface of the matrix. As drug is leached 
from the matrix the distance it must travel to reach the 
exterior of the matrix structure becomes greater presenting 
itself as drug depleted matrix dh. The other parameters 
involved in the description of release are as follows: 
Cs - solubility or saturation concentration of drug in 
the matrix. 
A - total concentration (amt. per unit volume) 
dissolved and undissolved. 
D - diffusion coefficient of the drug. 
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The increase in the distance that the drug must travel 
with time must be accounted for in the description of the rate 
of release. Therefore, the infinitesimal amount, dQ, of drug 
released because of this shift of the front is described by 
the linear ~xpression: 
dQ-Adh-l/2Csdh (2) 
substitution of the dQ term from Equation 2 into Equation 
1, integration, and solving for h yields: 
h- 4DCst 
2A-Cs 




which is known as the Higuchi Equation. Ordinarily, it is 
assumed that A » Cs and Equation 4 simplifies to: 
Q-{2ADCst (5) 
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This form of the Higuchi equation states that the amount 
of drug released is proportional to the square root of the 
following parameters: (Martin) 
A - total amount of drug per unit volume of the matrix. 
o - diffusion coefficient of the drug in the matrix. 
es = solubility of the drug in the polymeric matrix. 
t = time 
The Higuchi equation has been extended to further 
describe release of drug from a granular matrix. In this 
case, a granule is defined as a porous rather than a 
homogeneous matrix hence release involves the penetration of 
the matrix by the solvent, dissolution of drug, and leaching 
of the drug through interstitial channels and pores. The 
volume and length of these openings in the matrix must be 
accounted for in the previously established equation 
describing release from an erodible matrix system thus the 
Higuchi equation becomes: 
Q-~ D ~ (2A-€Cs) Cst (6) 
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where: 
E = total porosity of the matrix. 
T = tortuosity of the capillary system. 
Porosity, E, is defined as the fraction of the matrix 
that exists as pores or channels into which the surrounding 
liquid can penetrate. The porosity term which appears in 
Equation 6 is the total porosity of the matrix following 
extraction of its drug content. Therefore this term refers to 
any pore or channel which exists within the matrix structure 
that was created by an original air space, leaching of drug, 
or any other excipient. A mathematical description explains 
that total porosity E is a summation of initial porosity EO, 
porosity of drug Ed, and porosity due to other excipients Ee: 
(7) 
Tortuosity, T, is the second term which has been 
introduced to Equation 6 and its function is to account for an 
increase in the path length of diffusion due to branching and 
bending of the pores, as compared to the shortest "straight-
through" pores (Martin). For example, a channel having a 
direct, straight path to the matrix exterior possesses a 
tortuosity of unity, whereas an indirect, curving path would 
yield a much higher tortuosity rating (Desai and Higuchi). 
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Methods for determining porosity and tortuosity do exist 
but are beyond the scope of this research project. This brief 
introduction to drug release from matrix type delivery systems 
is presented to provide a basic understanding of matrix 
sustained release systems. A more detailed explanation can be 
found in a series of articles by Higuchi et al (Higuchi). 
2.6. Effect of Calcium Fillers on Dissolution 
A number of drugs on the pharmaceutical market are 
inherently potent and, therefore are administered at 
relatively low doses. In order for such a drug to be 
effectively delivered via an oral solid dosage form the drug 
must be formulated with other excipients to make it amenable 
to the tableting process. These inert excipients can 
constitute up to 95% of the formulation and therefore the 
effect of their physical and chemical properties on release of 
medicament from these formulations has been investigated. 
Lactose, calcium sulfate dihydrate, dibasic calcium 
phosphate dihydrate, and tribasic calcium phosphate are four 
excipients commonly employed in pharmaceutical formulations as 
fillers or diluents whose main purpose is to provide tablet 
bulk or weight. A study to determine their intrinsic 
dissolution rates (lOR) and its influence on drug dissolution 
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has been conducted (Koparkar). The study indicates a direct 
correlation between the IDR of the individual fillers and the 
rate of medicament release. From the data, it was ultimately 
concluded that the lDR of the filler in the formulation may be 
as important as its compressibility and physical stability. 
The study described above focuses upon medicament release 
from an immediate release formulation consisting of drug, 
filler, disintegrant, and lubricant. The study presented here 
focuses upon the solubility of the same calcium fillers, their 
correlation with release from a nondisintegrating tablet, and 
their matrix forming abilities. The results of the study are 
presented in detail in the following doctoral dissertation. 
Chapter III. Objectives 
The initial objective of the research project was to 
investigate the effect of the practically insoluble 
pharmaceutical diluents calcium sulfate dihydrate, dibasic 
calcium phosphate dihydrate, and tribasic calcium phosphate on 
the release of medicament from solid dosage forms. 
Acetaminophen was chosen as a model drug due to its relatively 
pH independent solubility profile over the range of interest, 
its directly compressible characteristic, and the ease with 
which it can be assayed. 
The release of medicament from a standardized tablet 
surface area was studied as a function of pH and solubility of 
the calcium diluent employed. The surface area of the 
experimental dosage form exposed to the dissolution media was 
standardized by coating the dosage form with synthetic 
spermaceti wax on all but one surface prior to testing. This 
coating process standardizes the tablet surface area exposed 
to the dissolution medium during testing and therefore 
eliminates any differences in total tablet surface area that 
may be attributable to the compressibility of the individual 
diluents. 
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Preliminary findings led to a more detailed study of the 
ability of calcium diluents to sustain the release of a model 
drug when the two are directly compressed into a solid dosage 
form. The study also focused on the identification of a 
mechanism by which the dosage form could be protected when in 
contact with acidic media. The calcium diluents exhibit 
higher solubilities in this environment and consequently do 
not retain their matrix structure or their ability to sustain 
medicament release. 
The primary purpose of this doctoral research project 
thus evolved into an investigation of the use of calcium 
diluents as matrix forming agents in sustained release solid 
dosage forms. The study also involved an evaluation of the 
effects of various formulation and processing variables on 
drug release from these novel sustained release vehicles. 
Monitoring of parameters in the production of the 
experimental dosage forms required the instrumentation of an 
existing Manesty F3 single station tablet press with a 
transducer strain gauge apparatus. Dissolution testing 
required the development of an in vitro protocol for the 
sampling and quantification of drug over a ten to twelve hour 
period during exposure to two different dissolution media. 
The result of this research project was the development 
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of a novel, directly compressible vehicle capable of 
sustaining release of a number of drug candidates over a ten 
to twelve hour period. An understanding of the control of 
medicament release rates via adjustment of two formulation 
parameters resulted as a consequence of the evaluation of this 
vehicle. 
51 
Chapter IV. Materials and Methods 
4.1. Materials 
The materials, suppliers, and lot numbers listed below 
were used in conducting the research presented in the 
following sections: 
acacia (Amend, Lot G18502B12) 
acetaminophen USP powder (Mallinckrodt, Lot 0048989D329) 
calcium sulfate dihydrate (Amend, Lot P34516B24) 
Carbopol 934P (BF Goodrich, Lot B844108) 
cellulose acetate phthalate NF (Eastman, Lot PM4380) 
cellulose acetate trimellitate (Eastman, Lot T002-1088) 
dibasic calcium phosphate dihydrate (Amend, Lot M9392M25) 
guar gum (Amend, Lot M32347H17) 
hydroxypropylmethylcellulose phthalate 55 (Eastman, Lot 
00302) 
magnesium stearate U8P (Ruger, Lot 225688) 
povidone USP (GAF, Lot 70111) 
synthetic spermaceti wax (Amend, LotS37171B12) 
tribasic calcium phosphate (Amend, Lot K28537M04) 
xanthan gum (Sigma, Lot 19F0503) 
4.2. Solubility Studies 
Solubility profiles were generated for the following 
calcium diluents; calcium sulfate dihydrate, dibasic calcium 
phosphate dihydrate, and tribasic calcium phosphate. A 
solubility profile was also generated for the model drug 








1000 ml O.lN HCl 
1000 ml acetate buffer pH 4.0 
1000 ml acetate buffer pH 5.5 
1000 ml phosphate buffer pH 6.5 
1000 ml phosphate buffer pH 7.5 
Pharma Test Model PTW S USP Dissolution 
Apparatus (paddle) at 100 RPM 
Hewlett Packard Diode Array Spectrophotometer 
Model 8451A 
2 micron filter after equilibrium 
4.2.2. Procedure 
An excess (10 gm) of each diluent; calcium sulfate 
dihydrate, dibasic calcium phosphate dihydrate, and tribasic 
calcium phosphate was placed in individual dissolution vessels 
(Pharma Test) each containing 1000 ml of media of pH 1.1, 4.0, 
5.5, 6.5, or 7.5. Each system was allowed to equilibrate for 
a three hour period under constant agitation supplied by a 
paddle apparatus operating at 100 RPM. Samples were taken, 
undissolved diluent was removed by vacuum filtration through 
a two micron filter, the USP titration procedure for calcium 
was performed on the filtrate, and calculations of the 
solubilities of the calcium diluents in the respective media 
were performed (Table 1, Figure 8). 
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An excess (30 gm) of acetaminophen USP powder was placed 
in each of five dissolution vessels containing 1000 ml of 
media of pH 1. 1, 4 . a , 5 . 5 , 6 . 5 , or 7. 5 . Each system was 
allowed to equilibrate under agitation provided by a paddle 
apparatus operating at 100 RPM for a three hour period. 
Samples were taken through a syringe equipped with a two 
micron filter. The samples were analyzed by 
spectrophotometric means at a wavelength of 244 nm. The 
solubility of acetaminophen at each pH was determined (Table 
2, Figure 9) by comparison of the absorbance values of these 
samples with the absorbance values of a series of standard 
solutions at each pH and the pH-solubility profile was 
generated (Figures 1 - 5). 
4.3. Tablet Manufacture 
Experimental tablets for both the preliminary and primary 
studies were manufactured by conventional direct compression 
techniques. The conditions and procedures by which their 
manufacture was performed appear in the following sections. 
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4.3.1. Preliminary Studies 
Preliminary studies consisted of evaluating drug release 
from a single surface consisting of drug and one of three 
calcium diluents in media of varying pH. The three diluents 
tested with acetaminophen were calcium sulfate dihydrate, 
dibasic calcium phosphate dihydrate, and tribasic calcium 
phosphate. 
4.3.1.1. Compression Conditions 
Tooling: 7 rom standard concave (Thomas 
Engineering Inc.) 
Compression: 4000 lbs 
Press: Carver Laboratory Press 
4.3.1.2. Procedure 
Tablets for the preliminary studies were prepared by 
weighing 100 mg of acetaminophen USP powder and 300 mg of the 
specified calcium diluent in a small weigh boat on a 
microbalance (Sartorius Model 4503 Micro). The two 
constituents were manually blended in the weigh boat with a 
stainless steel microspatula and compressed into a solid 
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pellet under the conditions stated in section 4.3.1.1. 
Following compression, each tablet was coated on all but 
one surface by placing the tablet on an upright punch and 
pouring melted synthetic spermaceti wax over the exposed 
portion of the tablet. The wax was allowed to dry and the 
coated tablet was removed from the punch by microspatula with 
the underside of the tablet remaining as the only uncoated 
surface. This procedure allows for the standardization of the 
total surface area of each individual dosage form that will be 
exposed to the dissolution medium during testing. 







9 rom standard concave (Thomas 
Engineering Inc.) 
4000 or 6000 lbs 
transducer mounted 
compression arm of 
Systems, Inc.) 
in shear pin of 
press (Measurement 
Manesty F3 single station tablet press 
(Manesty Division, Thomas Engineering, 
Inc. ) 
manual - weigh boat with microspatula 
v-blend in 500 gm capacity lab model 
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4.3.2.2. Procedure 
Experimental tablets for the primary dissolution studies 
were prepared by weighing the excipients in the proportions 
specified in the individual studies to total 100 gm. These 
excipients were screened through a 10 mesh sieve prior to 
mixing for the specified period of time in the v-blender. A 
400 mg aliquot of each blend was weighed on a microbalance and 
compressed manually on a single station press (Manesty F3) 
under 4000 or 6000 lbs of force. 
4.3.2.3. strain Gauge Apparatus 
An existing single station tablet press (Manesty, Model 
F3) was instrumented with a transducer type strain gauge 
apparatus (Measurement Systems Inc.) for monitoring 
compression force employed during the manufacture of 
experimental tablets. This was accomplished by constructing 
a replica of the existing compression arm shear pin in 
collaboration with Measurement Systems Inc. into which the 
transducer was installed. The replica shear pin was installed 
in the press and linked to a digital readout device (DCI 
Inc.). The transducer output signal was amplified and 
converted to a direct readout of force in pounds applied 
during the compression cycle. 
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4.4. Dissolution 
An automated sampling (ISCO, Tris) and data processing 
system (Hewlett Packard, DODIS*51) was employed to evaluate 
the release profiles of the tablet formulations in both the 
preliminary and primary release studies. 
4.4.1. Preliminary Studies 
The following conditions and procedures were used to 
evaluate the release of the model drug acetaminophen from 
blends of drug and one of three calcium diluents in media of 
varying pH. 
4.4.1.1. Conditions 
Dissolution Media: 1000 ml of O.lN HCl (pH 1.2 - 1.4) 
1000 ml of acetate buffer (pH 4.0) 
1000 ml of acetate buffer (pH 5.5) 
1000 ml of phosphate buffer 
(pH 6. 5) 





Tablets - USP apparatus #X (paddle) 
at 50 RPM 
Hewlett Packard Diode Array 
Spectrophotometer Model 8451A 
Hewlett Packard Single Wavelength 
Detection Dissolution Software 
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Program DODIS*51 
Sampling: Every 60 min for 480 min via a 
an automated sampling device 
equipped wi th a 2 micron 
filter 
Analytical 
wavelength: 244 nm for acetaminophen 
4.4.1.2. Procedure 
Experimental tablets described in section 4.3.1.2. 
containing drug and diluent were placed in a dissolution 
vessel containing 1000 ml of media of varying pH values as 
specified in section 4.3.1.1. with the uncoated tablet surface 
facing upward to ensure maximum exposure to the aqueous 
environment. Agitation was supplied by a paddle apparatus 
rotating at 50 RPM with a temperature of 37°C being maintained 
throughout the testing period. 
Each system was sampled automatically at 60 min intervals 
via a two micron filter and analyzed for drug content at a 
wavelength of 244 nm on a diode array ultraviolet 
spectrophotometer (Hewlett Packard, Model 8451A). Absorbance 
values were obtained and the percent drug versus time profiles 
were generated with respect to Beer's Law and reference to a 
series of standard solutions presented in the following 
section. Calculations were performed via an on-line 
dissolution software package (Hewlett Packard, Program 
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DOD1S*51). 
4.4.2. Primary Studies 
Primary studies were conducted to evaluate release of 
drug from whole tablets containing drug, diluent, and other 
excipients. 
4.4.2.1. Conditions 
Dissolution Media: 1000 ml of O.lN HCl (pH 1.2 - 1.4) 
for two hours 
1000 ml of phosphate buffer (pH 7.1 
- 7.2) for duration of test 
Temperature: 37°C 
Apparatus: Tablets USP apparatus # 1 
Analytical 
Wavelength: 
(basket) at 50 and 100 RPM 
Pharma Test Model PTW S six vessel 
dissolution apparatus 
Tris automated sampling system 
Hewlett Packard Diode Array 
Spectrophotometer Model 8451A 
Hewlett Packard Single Wavelength 
Detection Dissolution Software 
Program DODIS*51 
244 nm for acetaminophen 
270 nm for theophylline 
266 nm for chlorpheniramine maleate 
in O.1N Hel 
264 nm for chlorpheniramine maleate 
in phosphate buffer 
Cell Pathlength: 
Sampling: 
0.1 cm for acetaminophen 
0.1 cm for theophylline 
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1.0 cm for chlorpheniramine maleate 
Every 60 min for two hours in 
O.lN HCI 
Every 60 min for duration 
test in phosphate buffer 




The uncoated experimental tablets described in section 
4.3.2.2. consisting of drug, diluent, polymer, binder, and 
lubricant totalling 400 mg in weight were placed in a basket 
apparatus in 1000 ml dissolution vessels containing 1000 ml of 
O.lN HCl. The proportions of each excipient contained in the 
tablets are specified in the individual sections of Chapter V. 
The tablets were rotated at 50 and 100 RPM with the test media 
being maintained at 37°C with samples taken automatically 
through a two micron filter every 60 min for a period of two 
hours. 
Upon completion of the initial two hour testing period 
the rotation of the baskets containing the tablets was 
terminated and the baskets were raised from the individual 
dissolution vessels. The O.lN Hel media was replaced with 
1000 ml of phosphate buffer (pH 7.1 - 7.2) which had been 
preheated to 37°C. The baskets were then lowered into the 
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media and testing was resumed for an additional period of 
time. Samples were taken automatically every 60 min through 
a two micron filter, analyzed spectrophotometrically, and 
absorbance data was processed to determine the percent of drug 
released at that particular time. Percent drug versus time 
data was generated in hard copy form by a single wavelength 
detection dissolution software program (Hewlett Packard, 
Program DOOOS*51) . 
4.4.2.3. Standard Solutions 
Standard solutions series of each of the drug candidates 
tested in this research project were prepared and analyzed for 
linearity of absorbance versus concentration data. These 
analyses validate the adherence to Beer's Law in the 
calculation of the percent drug released data via comparison 
of absorbance values obtained from the samples tested and that 
obtained from a prepared standard solution equivalent to 100% 
of drug release. Best fit regression plots for acetaminophen, 
theophylline, and chlorpheniramine standard solutions appear 
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4.5. statistical Analysis of Data 
Data was reported on a percent~drug,,'"'releasedM~versus ... time 
(minutes) basis and also on a percent released versus square 
root of time basis. The latter was determined to evaluate the 
linear relationship between percent released and square root 
of time which is a standard analysis performed on matrix type 
drug delivery systems. standard deviation and percent 
relative standard deviation information was determined as 
indicators of distribution of data points at any given 
sampling interval. Release profiles, regression statistics, 
and line of best fit plots were determined as evidence of 
existence of a matrix diffusional drug delivery system and in 
comparison of drug release from different sustained release 
vehicles. All statistical analyses involving direct 
comparison of individual data points were performed via two 
sample analysis of variance (ANOVA) using the statgraphics 
computer software (statistical Graphics Corporation) . 
Regression analyses were generated via the Graph Scientific 
Plotting and Data Transformation (Micromath Inc.). All plots 
were generated on a Hewlett Packard Series II Laserjet 
Printer. 
Chapter V. Experimental and Results 
5.1. Preliminary Studies 
Preliminary studies were conducted to investigate the 
effect of the poorly soluble diluents calcium sulfate 
dihydrate, dibasic calcium phosphate dihydrate, and tribasic 
calcium phosphate on the release of medicament from solid 
dosage forms. 
5.1.1. Solubility Profiles 
Solubility profiles were generated for the three calcium 
diluents and the model drug acetaminophen in the preliminary 
studies. 
5.1.1.1. Calcium Diluents 
Solubility determinations for calcium sulfate dihydrate 
NF, dibasic calcium phosphate dihydrate USP, and tribasic 
calcium phosphate NF were generated by placing an excess (30 
gm) of diluent in the media of interest and allowing to 
equilibrate for three hours. Samples were taken via vacuum 
filtration through a two micron filter and analyzed for 
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diluent concentration via the USP titration for calcium. 
Determinations were performed in O.lN HCI, acetate buffer (pH 
4.0 and 5.5), and phosphate buffer (pH 6.5 and 7.5) for each 
compound as outlined in sections 4.2.1. and 4.2.2. 
Table 1 and Figure 8 summarize results obtained from 
these studies for all three diluents all of which exhibit 
their highest solubility values at pH 1. 1 with a range of 
17.39 mg/ml for tribasic calcium phosphate to 8.02 mg/ml for 
calcium sulfate dihydrate. Their solubilities decreased to 
practically insoluble levels at pH 6.5 and 7.5. 
5.1.1.2. Acetaminophen 
A solubility profile of the model drug acetaminophen was 
generated by placing an excess of acetaminophen powder USP in 
O.lN HCI, acetate buffer (pH 4. 0 and 5. 5), and phosphate 
buffer (pH 6. 5 and 7.5) and allowing to equilibrate for a 
sufficient period of time. Samples were processed and 
analyzed as outlined in sections 4.2.1. and 4.2.2. and the 
resultant data is presented in Table 2 and Figure 9. 
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Table 1. solubility Data for Three Calcium Diluents 
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5.1.2. Experimental Tablets 
Tablets for the preliminary dissolution studies were 
manufactured by weighing approximately 300 mg of diluent and 
100 mg of acetaminophen USP powder in a small weigh boat and 
blending with a microspatula. The blend was then filled into 
a 7 mm die on a Carver Laboratory Press and compressed into a 
solid mass under ~ 4000 lbs. of pressure. The 400 mg total 
tablet weight and the 25% drug loading were chosen as 
arbitrary representations of a practical tablet weight and 
drug content. 
Prior to dissolution testing the dosage form was coated 
on all but one surface with synthetic spermaceti wax by the 
procedure outlined in section 4. 3 .1.2 . This was done to 
standardize the tablet surface area exposed to the dissolution 
media during testing. 
5.1.3. Dissolution Testing 
Dissolution testing was performed in triplicate by 
placing tablets from each drug-diluent blend in 1000 ml of 
media of pH 1.1, 4.0, 5.5, 6.5, and 7.5. The tablets were 
subj ected to the USP paddle method under the condi tions 
outlined in section 4.4.1.1. with samples taken and analyzed 
every 60 min for an eight hour period. 
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Release profiles 
generated from triplicate runs are shown in Figures 10, 11, 
and 12. Spectrophotometric analysis for acetaminophen content 
was performed at 244 nm. A least squares linear regression 
analysis was performed for the percent drug released and the 
square root of time data in media of pH 1.1, 4.0, 5.5., 6.5, 
and 7.5 and are presented in Tables 3,4,5 and Figures 
13,14,15. 
5.2. Primary Studies 
The results obtained in the preliminary studies led to a 
more detailed investigation of the use of calcium sulfate 
dihydrate, dibasic calcium phosphate dihydrate, and tribasic 
calcium phosphate as matrix forming materials in sustained 
release solid dosage forms. 
5.2.1. Acid Resistivity 
Drug release profiles (Figures 13, 14, 15) and inspection 
of the dosage forms during testing revealed that the directly 
compressible blend of drug and diluent at pH 1. 1 does not 
possess the ability to sustain the release of medicament over 
an extended period of time. This is due to the higher 
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Figure 10 
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Figure 12 
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Table 3. statistics of Least Squares Linear Regression of 
Percent Acetaminophen Released on the Square Root of 
Time (min) as a Function of pH with Calcium Sulfate 
Dihydrate as Diluent 
..... :- ... 
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. St:.c:l.t-~S.t. ~ q _.: : -: .. 4. ·0 : §::;~A:;:· :::- 6 ·. 5 7 • 5 .. -1.1 
.. ."::-:. - ...... . 
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Figure 14 
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Table 4. statistics of Least Squares Linear Regression of 
Percent Acetaminophen Released on the Square Root of 
Time (min) as a Function of pH with Dibasic Calcium 
Phosphate Dihydrate as Diluent 
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Figure 15 
Regression of % Drug on Sqr t of Time 
TI 



































75% Tr ibaslc Calcium 
Phosphate 
pH 
• (I (I I) 
QJ 
~ -20 J------T------+------+------~----_+----~ 
0.0 4.0 8.0 12.0 16 .0 20.0 24 .0 
Sqrt Time (mIn) 
Table 5. statistics of Least Squares Linear Regression of 
Percent Acetaminophen Released on the Square Root of 
Time (min) as a Function of pH with Tribasic Calcium 
Phosphate as Diluent 
pH of Test Mediunl 
statist.i.c 1.1 4 '.0 5.5 6 :.5 · 7.5 
. 
R-Squared .971 .993 .994 .994 .988 
C.O .. D . . " .867 .975 .977 .978 .961 
Carr. .931 .987 .988 .989 .981 
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solubility of the diluent at pH 1.1 and its ultimate release 
into the media during testing causing a degradation of the 
tablet matrix. 
To address this problem a series of screening tests were 
conducted to evaluate the feasibility of imparting a more acid 
resistant or,protective character on the dosage form by the 
addition of other pharmaceutical excipients. Initial 
screening was conducted by blending the excipients with drug 
and calcium sulfate dihydrate, compressing the blend, and 
placing the dosage form in O.lN HCl overnight with no 
agitation. The dosage forms were observed to determine the 
effects of this exposure on their appearance. 
The pharmaceutical excipients chosen for screening fall 
into the categories of natural gums, synthetic polymers, and 
enteric materials. Materials tested included guar gum, 
xanthan gum, acacia, povidone USP, hydroxypropyl-
methylcellulose, cellulose acetate phthalate NF, Carbopol 
934P, cellulose acetate trimellitate, and hydroxypropyl-
methylcellulose phthalate 55. 
Results (Table 6) of the screening indicate that a 
vehicle containing calcium sulfate dihydrate, acetaminophen, 
and acacia remained intact overnight in a beaker of O.lN HCl. 
The formulation containing Carbopol 934P formed a continuous 
Table 6. Observations from Acid Resistivity screening using 
various Excipients 
EXCIPIENT % CO~:ENT·/O~S .• ~yA'l'IQ!l: .... 
Guar Gum 5 Disintegrated immediately 
Guar Gum 15 Disintegrated immediately 
Acacia 10 Remained intact overnight 
Acacia 15 Remained intact overnight 
HPMC 5 Flaking of dosage form 
HPMCP S5 15 Capping immediately 
CAP 5 Capping, flaking, etc. 
CAT 5 Capping, lamination, etc. 
Carbopol 5 Gel/pasty mass 
Carbopol 15 Large swollen gel-like mass 
xanthan 15 Disintegrated slowly 
Povidone 20 Eroded rapidly 
All formulations contained calcium sulfate dihydrate as 
diluent and acetaminophen as model drug. 
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gel-like mass under the same conditions. All screening 
studies were conducted with calcium sulfate dihydrate as 
diluent. 
5.2.1.1. Acacia 
An experiment was conducted to investigate the effects of 
the level of acacia and on the release of medicament in O.lN 
Hel. Tablets were manufactured on a Manesty F3 single station 
tablet press equipped with a strain gauge apparatus 
(Measurement Systems Inc.) and 9 rom standard concave tooling 
(Thomas Engineering Inc. ) via the procedure outlined in 
section 4.3.2.1. Tablets were tested in duplicate and the 
results are given in Table 7. All formulations released 100% 
of their drug content within a two hour period and thus 
warranted investigation of additional approaches to the 
protection of the dosage form in the presence of O.lN HCl. 
5.2.1.2. Carbopol 934P 
A knowledge of the gelling ability of Carbopol 934P at 
low concentrations and results (Table 6) from the preliminary 
acid resistivity screening study led to an investigation of 
its effect on release of medicament from this vehicle. 
Table 7 • Percent Acetaminophen Released from 
containing Calcium Sulfate Dihydrate 
Different Levels of Acacia in O.lN Hel 




% Acacia 5% 25% 
Compression F. 4000 lbs 4000 Ibs 



































The experimental tablets were prepared as outlined in 
section 4.3.2. employing a 20% drug load, calcium sulfate 
dihydrate, a specified level of Carbopol 934P (5 or 15%), and 
0.5% magnesium stearate USP as lubricant. This level of 
magnesium stearate was employed to aid in the tableting 
process. Results (Table 8) indicate that both levels of 
Carbopol 934P (5 & 15%) sustain the release of acetaminophen 
over a four hour period in O.IN HCl. 
5.2.1.3. Carbopol 934P/Acacia Combination 
Observations in the initial acid resistivity screening 
studies (Table 6) which were conducted in a static environment 
indicate that a 5% level of acacia in a formulation of drug, 
calcium sulfate dihydrate, and magnesium stearate may maintain 
a solid tablet structure in the presence of O.IN HCI for an 
extended period of time. 
Preliminary screening static environment studies (Tables 
6 and 8) had also shown that a 5% level of Carbopol 934P 
incorporated with drug, calcium sulfate dihydrate and 
magnesium stearate yielded a dosage form which forms a ge1-
like pasty mass upon introduction to O.IN HCI. 
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Table 8. Percent Acetaminophen Released from Vehicle 
containing Calcium Sulfate Dihydrate, Acacia, and 
Two Levels of Carbopol 934P in O.lN Hel 
... ::.:.. ... . .. :.. :::::::: .. : . .. : .. . ......... : 
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Examination of the dosage forms during these initial 
studies led to a postulation of the use of acacia and Carbopol 
934P in combination. Acacia had shown the ability to assist 
in prolonging the existence of the matrix structure in the 
presence of O.lN HCl and to cause its degradation to occur via 
an erosive mechanism as opposed to its total dissociation 
and/or disintegration. Meanwhile, preliminary studies 
employing Carbopol 934P resulted in a gel-like pasty but 
continuous mass at levels as low as 5%. 
Release studies were then conducted employing Carbopol 
934P at levels of 1,3, or 5%,25% acacia, drug, calcium 
sulfate dihydrate, and 0.5% magnesium stearate. Results are 
presented in Figure 16 and Table 9. The dissolution protocol 
involved the exposure of the dosage form to O.lN Hel for an 
initial two hours with subsequent exposure to buffer (pH 7.2) 
for the duration of the testing period. The testing procedure 
is outlined in section 4.4.1. 
5.2.2. Processing and Formulation Variables 
with the establishment of ability of a vehicle of 
Carbopol 934P, acacia, calcium sulfate dihydrate, and 
magnesium stearate to deliver drug at a controlled rate over 
an extended period of time additional studies were conducted 
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Table 9. Percent Acetaminophen Released from Vehicles 
containing Calcium Sulfate Dihydrate and Three 
Different Levels of Carbopol 934P 
... 
.. 
: Time 0%<· .. 
I···· 
··lminl ........ 
I: 60 43 43 
120 77 74 
.: .. 
. ··180 88 86 
·2:40 92 91 
300 95 94 
360 96 96 
4·20 97 97 
480 NA NA 
540 99 100 











































































% RcetaminophEn RElEaSEd vs Sqrt Time 
120 
TI 
Ca Ie ium SuI fate Dihydrate 
OJ as Diluent 0% Carbopol 
Ul 100 -+ --+- --+- -----+-rn 25% Rcacia OJ -.- --
--1 /+'-
OJ " 1% Carbopol cr 80 D.1N HCl (2 hr) ""e----+" ,.e---c + .. ...0'--
OJ "" 




60 I ff Q I Carbopol I 
I / 
0 ft c I I 
-----1 I 
E 40 / • -0 --- 0 rn -s- -








0.0 5.0 10.0 15.0 20.0 25.0 
Sqrt TimE (min) 
95 
in an attempt to further evaluate its mechanics and release 
characteristics. 
The effects of a few processing and formulation variables 
on the release of medicament from this vehicle were the focus 
of this series of studies. Mixing time, mixing intensity, 
compression force, level of Carbopol 934P, level of acacia, 
and type of diluent were the specific investigated. 
5.2.2.1. Mixing Time and Mixing Intensity 
The manufacture of experimental tablets in the initial 
screening and dissolution studies consisted of weighing the 
components of each individual tablet and blending in a small 
weigh boat with microspatula prior to compression as outlined 
in section 4.3.1. To provide a comparison of a higher mixing 
intensity, powder blends totalling 200 gm in weight of 
Carbopol 934P, acacia, calcium sulfate dihydrate, and 
magnesium stearate were prepared in a laboratory model twin 
shell v-blender. In addition, the effect of total mixing time 
on the performance of the vehicle was studied by preparing 
tablets from 400 mg aliquots taken after 5, 20, and 45 minutes 
of mixing and compressing under 4000 lbs of force. Details of 
the procedure are outlined in section 4.3.2. 
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Drug release was measured from two tablets from each 
mixing time with all tablets containing 5% Carbopol 934P, 25% 
acacia, drug, calcium sulfate dihydrate, and 0.5% magnesium 
stearate. The dosage forms were exposed to O.lN HCI for an 
initial two hours with subsequent exposure to phosphate buffer 
(pH 7.2) for the duration of the testing period. Results are 
presented in Tables 10 and 11. A two sample analysis of 
variance of the percent drug released at specified times from 
the vehicles manufactured with two different levels of mixing 
intensity and three mixing times were performed on the 
duplicate runs (statistics Appendix, Mixing). This 
statistical format was used to provide a direct comparison of 
the drug release from each vehicle at given times. Release 
data was evaluated at 60 and 480 min to represent initial and 
terminal release characteristics. The effect of mixing time 
on the release of medicament from a vehicle containing 5% 
Carbopol 934P, 25% acacia, calcium sulfate dihydrate, and 0.5% 
magnesium stearate was also evaluated (Statistical Appendix, 
Mixing Section). 
5.2.2.2. Compression Force 
A matrix sustained release system provides a channel like 
infrastructure from which drug is released by a diffusional 
process upon introduction to the aqueous environment of the 
Ie 10. Percent 
I 1 
e i hen eleas from Three 
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Compression force applied in the 
manufacture of such tablets can effect this channel structure 
and thus was investigated for its effect on release from the 
vehicle presented here. 
Experimental tablets were manufactured for the study by 
blending the excipients, sampling the blend, and compressing 
the sample under the conditions outlined in Section 4.3.2. 
This study was conducted in conjunction with the mixing time 
study which established the release as independent of mixing 
time, and therefore, the effect of compression forces of 4000 
and 6000 lbs were evaluated. Compression force was monitored 
as outlined in section 4.3.2.3 via a digital readout meter. 
Results are presented in Figure 17. 
5.2.3. Formulation Variables 
Initial screening studies revealed that the formulation 
of Carbopol 934P (5%) and acacia (25%) with calcium diluent 
and magnesium stearate (0.5%) yielded a directly compressible 
vehicle capable of sustaining the release of the model drug 
acetaminophen over a 10 to 12 hr period. Additional studies 
were conducted to evaluate the effect of changing both the 
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5.2.3.1. Carbopol 934P 
The presence of Carbopol 934P in this vehicle provides a 
gelling characteristic which forms a protective barrier about 
the exterior of the dosage form upon introduction to an 
aqueous environment. To study the effect of the level of 
Carbopol 934P, dosage forms were tested in duplicate at levels 
of 0, 1, 3, and 5% Carbopol 934P while maintaining levels of 
20% acetaminophen, 25% acacia, and 0.5% magnesium stearate. 
Calcium sulfate dihydrate was employed as a matrix forming 
diluent at levels sufficient to yield a 400 mg total tablet 
weight. All dosage forms were manufactured under the 
conditions outlined in section 4.3.2. Results are presented 
in Table 12 and Figure 18. 
A statistical analysis of the release of medicament from 
vehicles containing 0, 1, 3, and 5% Carbopol 934P in 
combination with 25% acacia, calcium sulfate dihydrate, and 
O. 5% magnesium stearate was performed on 60 and 600 min 
release data (statistical Appendix, Carbopol Section). A 
least squares linear regression analysis at a 95% confidence 
level provides mathematical insight to medicament release from 
these vehicles. Regression statistics are presented in Table 
12 and Figure 19. 
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Table 12. Percent Acetaminophen Released from Vehicles 
containing Calcium Sulfate Dihydrate as Diluent and 
Four Levels of Carbopol 934P 
43 43 28 25 
77 74 44 38 35 21 
88 86 55 50 43 45 25 
91 62 57 50 53 30 
95 94 68 62 56 60 34 
96 96 73 68 61 65 38 
97 97 77 72 66 71 41 
NA NA NA NA NA 44 
99 100 84 79 75 79 
99 100 88 82 78 
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5.2 .. 3 .. 2 .. 
It has been established that a vehicle contain 5% 
Carhopol 934P, 25% acacia, calcium sulfate dihydrate, and 0 .. 5% 
find 
ium stearate is capable of releasing drug in a susta 
ion over an extended period of time.. Based on 
an investigation of the effect of the level of acac 
on medicament re was initiated .. 
Preliminary studies showed that 25% acac when 
combination with Carbopol 934P (1 ..... 5%) and calcium 
ihydrate is capable of sustaining the release of 
acetaminophen over an eight hour period of time ( 
1 
16, ion 5.2 .. 1 .. 3 .. ) .. Experimental tablets containing 15 or 
20% , 5% Carbopol 934P, calcium sulfate dihydrate, 0 .. 5% 
magnesium stearate, and 20% acetaminophen were in 
triplicate for comparison with the 25% vehicle.. All dosage 
forms were manufactured and tested under the conditions 
I in ion 4 .. 3 .. 2.. Results are summariz in Table 13 
20. 
A two samp analysis of variance (statistical Appendix, 
1 ion) was performed to provide a direct ison 
the release profiles generated from the three vehicles 
(Table 13). Sixty and 600 min data were chosen for ana is 
as representatives of initial and terminal release profiles of 
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Table 13. Percent Acetaminophen Released from sustained 
Release Vehicle Employing Three Levels of Acacia 
0 0 0 
23 22 23 22 23 
36 34 34 33 35 33 21 
45 42 42 43 43 26 
53 50 49 50 49 30 
60 57 56 57 55 34 
66 63 62 62 63 62 38 
72 68 68 68 68 67 41 
77 74 72 73 72 72 45 
Least Squares LillearRegressionBtatistics 0 





































the dosage forms. A least squares linear regression analysis 
(Table 13, Figure 20) indicates a strong linear relationship 
between the percent drug released and the square root of time 
for all three of the vehicles. R-squared values of .99964, 
.99955, and .99965 resulted for the vehicles containing 15, 
20, and 25% acacia. 
5.2.3.3. Dibasic Calcium Phosphate Dihydrate 
Carbopol 934P and acacia have shown the ability when used 
in combination with calcium sulfate dihydrate to sustain the 
release of the model drug acetaminophen over a 10 hr period 
via a matrix type delivery system. Based on these findings 
and preliminary studies revealing the ability of dibasic 
calcium phosphate dihydrate to exhibit similar characteristics 
when directly compressed with drug a study was conducted to 
evaluate its employment into this sustained release vehicle. 
A vehicle containing 5% Carbopol 934P, 25% acacia, 
dibasic calcium phosphate dihydrate, and 0.5% magnesium 
stearate was tested and the data (Table 14) shows an average 
of 97.5% drug release over a 10 hr period. Subsequent testing 
of dosage forms containing 1 and 3% Carbopol 934P (Table 15) 
show release of 100 and 98.1% drug. 
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Table 14. Release Values of Acetaminophen from Vehicle with 
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36 37 39 
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Table 15. Release Values of Acetaminophen from Vehicles 
with Dibasic Calcium Phosphate Dihydrate as 
Matrix Forming Agent 
62 .. 8 
94 .. 8 100 .. 2 
98 .. 0 101 .. 4 
99 .. 0 101 .. 4 
99 .. 4 101 .. 5 
101.5 
99.4 101 .. 5 
99 .. 101.5 
99 .. 4 101 .. 5 
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A least squares linear regression analysis (Table 15, 
Figure 21) of the percent drug released versus the square root 
of time yielded r-squared values of .967, .992, and .998 for 
the vehicles containing 1, 3, and 5% Carbopol 934P. 
5.2.3.4. Tribasic Calcium Phosphate 
A study of the use of tribasic calcium phosphate in 
combination with 5% Carbopol 934P and 25% acacia was conducted 
for comparison with the vehicles previously investigated 
employing the diluents calcium sulfate dihydrate and dibasic 
calcium phosphate dihydrate. 
, 
The data (Table 16) indicates an average release of 100% 
of the drug content of the dosage form in six hours. The 
dosage form exhibited • erOS.lon from its outer surface 
immediately following its introduction into O.lN HCl and 
ultimately disappeared in five to six hours. Due to the 
erosive behavior and ultimate total disintegration of this 
vehicle during testing no further investigation of the 
employment of tribasic calcium phosphate was conducted. 
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Table 16. Release Values of Acetaminophen from Vehicle 
with Tribasic Calcium Phosphate as Diluent 
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5.2.4. Other Drug Candidates 
The pharmaceutical diluents; calcium sulfate dihydrate 
and dibasic calcium phosphate dihydrate when formulated with 
Carbopol 934P, acacia, and magnesium stearate have shown the 
abili ty to sustain the release of the model drug 
acetaminophen. The system releases drug via a 
nondisintegrating matrix type mechanism when calcium sulfate 
dihydrate is employed as diluent, with release occurring by 
partial erosion and matrix delivery with the employment of 
dibasic calcium phosphate dihydrate. 
The data obtained from these studies employing the model 
drug acetaminophen allowed for an understanding of the 
sustained release capabilities of this vehicle. Realization 
of the impracticality of acetaminophen as a viable sustained 
release candidate due to its inherently high dose and a 
curiosity of the ability of the vehicle to deliver more 
practical sustained release candidates led to an investigation 
of the incorporation of the drugs theophylline and 
chlorpheniramine maleate. 
5.2.4.1. Theophylline 
Experimental tablets consisting of 25% of the drug 
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theophylline, 5% Carhopol 934P, 25% acacia, calcium sulfate 
diluent, and 0.5% magnesium stearatewere prepared as outlined 
in section 4.3.2. The diluent employed was either calcium 
sulfate dihydrate or dibasic calcium phosphate dihydrate. The 
conditions employed in their manufacture and testing are 
outlined in Section 4.3.2. 
Results (Table 17, Figure 22) indicate a 62.53% release 
of drug over a 10 hr period from the vehicle containing 
calcium sulfate dihydrate and a 93 . 65% release from the 
vehicle containing dibasic calcium phosphate dihydrate. The 
calcium sulfate dihydrate vehicle remained practically intact 
throughout the release process while the dibasic calcium 
phosphate dihydrate vehicle existed as a loose gel-like pasty 
mass. 
The initial weight of each tablet was 400 mg and to 
demonstrate how the calcium sulfate dihydrate vehicle releases 
drug via a matrix diffusional process the tablets were dried 
overnight and weighed following testing. Of the three tablets 
tested the resultant final weights were 212, 229, and 216 mg, 
respectively, with an average of 66.00% of drug having been 
released from each tablet (Table 17). 
The study of theophylline release from vehicles 
consisting of 5% Carhopol 934P, 25% acacia, calcium sulfate 
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Table 17. Release Values of Theophylline from Vehicle 
Containing Calcium Sulfate Dihydrate or Dibasic 
Calcium Phosphate Dihydrate as Diluent 
.: .. : ... :-
.. ,- .. ,".-, . . ." ............ , .... , .. 
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300 46 46 
360 50 50 
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480 57 57 
540 60 60 

















CaHP04 2H20 or CaS04 
. .. , . . . . . . , . . . , . . . .. .... 
%RSD . Di:bj.Sl.:q::.·ca·l c i um . 
. Pbo$pll.~:1:·~ 
1.6 19 NA 19 
1.5 29 27 29 
.58 39 40 39 
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Figure 22 
Percent Drug ReleasEd vs Sqrt lime 
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dihydrate, and 0.5% magnesium stearate was extended to 
evaluate the effect of the levels of Carbopol 934P and acacia 
on the performance of the dosage form. Results are presented 
in Table 18 and Figure 23. A least squares linear regression 
analysis of the percent theophylline released and the square 
root of time yielded r-squared values of .989, .998, and .999 
for the vehicles containing 1, 3 and 5% Carbopol 934P. 
Additional studies were conducted in which three 
formulations were tested with all three containing 25% 
theophylline, calcium sulfate dihydrate, and 0.5% magnesium 
stearate. The first formulation also contained 25% acacia but 
was void of Carbopol 934P, the second contained 5% Carbopol 
934P but was void of acacia, and the third contained 10% 
acacia and 5% Carbopol 934P. Results (Table 19, Figure 24) 
indicate an average of 100% drug release in two hours from the 
first formulation, a 100% release in three hours for the 
second, and only a 32.41% release in the first two hours for 
the third. The third formulation released 68.85% of its drug 
content over the entire ten hour period. Results are 
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5.2.4.2. Chlorpheniramine Maleate 
Chlorpheniramine maleate is an agent which is a common 
sustained release candidate possessing a much higher 
solubility (50 mg/ml) in the presence of O.lN HCl than 
acetaminophen (23 mg/ml) and theophylline (10 mg/ml) 
(Analytical Profiles). Its incorporation into the vehicle of 
Carbopol 934P, acacia, calcium sulfate dihydrate, and 
magnesium stearate is an ultimate test of the ability of the 
vehicle to sustain the release of a highly soluble drug. 
Tablets were manufactured as described in section 4.4.1. 
with a chlorpheniramine maleate content of 2.5% which 
constitutes a 10 mg dose for delivery over a ten to twelve 
hour period (Facts and Comparisons). Formulations containing 
1, 3, and 5% Carbopol 934P and 25% acacia with calcium sulfate 
dihydrate were manufactured and tested under the conditions 
outlined in section 4.4.2. Results (Table 20, Figure 25) 
indicate average release values of 101.3, 82.25, and 71.75% 
from the 1, 3, and 5% vehicles over an eight hour period. The 
tablets were dried overnight and weighed with final weights of 
151 and 150 mg resulting for the 1% vehicle, 243 and 210 mg 
for the 3% vehicle, and 244 and 238 mg for the 5% vehicle. 
Additional studies were conducted to evaluate the effect 
of the level of acacia on the performance of the vehicle with 
124 
Table 20. Release Values of Chlorpheniramine Maleate from 
Vehicles containing Calcium Sulfate Dihydrate as 
Matrix Forming Agent with Three Different Levels of 
Carbopol 934P 
53 59 43 48 42 41 
78 87 57 68 55 56 
89 94 63 77 62 60 
95 97 67 81 64 64 
98 98 69 83 67 66 
100 99 71 86 69 68 
102 99 73 88 70 70 
102 100 75 90 72 71 
151 150 243 210 244 238 
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Table 21. Release Values of Chlorpheniramine Maleate from 
Vehicles containing Calcium Sulfate Dihydrate as 
Matrix Forming Agent with Four Different Levels of 
Acacia 
.:::::>.:: • .... ..... ·· ,y '· . .. : ... . >:':' 
. . . . , 
. ...... , ... ' ...... .... ,- .. , .. . . . ... . 
.•.. ' , - . :- :-: ." :-:.::- :~, " , ... :: . .:~ ... :.:~<~ :>:. <::.:: ~:~: 
. .. . . . .. .', ' , . 
"..::.~ ':c 
':.:::::: .6..0:))::;:::: 
.. . ' . . ' ...... , .. .. ,',', 42 51 45 41 46 42 42' 41 .':': •. 
. " .. . . 
69 61 56 60 57 55 55 
- ... . . . ... . 
.:.: '::.' .• ~~ .. ;g.::.:«, 57 
, , ',- .. , .... ... , ., .. ,., .. '. ' .. 
: ··>~8·:<r ··/H 70 86 70 65 70 " 67 62 60 
:':· :-2:4:0 :.· ..... ::::: 73 89 73 68 72 70 64 64 .. ... . ,. ' ,- , 
. " .' ~ >. ' . .'-: .. ' '. ::.... . . , 
, .... . " , . 
'. ··· 3::~r(j ' 75 91 75 70 75 72 67 66 
. , . - ' . . . . ~ 
.·.- :~, ~. P\ .. . 77 93 77 72 77 75 69 08 
79,: 94 78 73 78 76 70 70 
. - . .. . , ... , ... , ..... .. .... -..... ' .. ,.,., 
.. ';'.: .... 4>· "'8" '.: ·0··:·':·· ·:.:·:···· .. ::...:.<: / .. :.<\/.)::: . 80 96 80 76 84 79 72 71 
. - ... , , ....... .. . , ' , . .. , . . '~' 
:::- ::::: .. §:.~-q:./!:?+:: 82 98 NA NA NA NA NA NA 
NA NA NA NA NA NA NA 
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NA 100 79 84 82 NA NA 
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chlorpheniramine maleate. Results (Table 21, Figure 26) 
indicate 92.60, 82.3, 84.6%, and 71.75% drug release from 
vehicles containing 5% Carbopol 934P and 10, 15, 20%, and 25% 
acacia, respectively, in a twelve hour period. The tablets 
which remained after testing were dried overnight and weighed 
with final weights of 263 and 288 mg for the 10%, 267 and 275 
mg for the 15%, 254 and 259 mg for the 20%, and 244 and 238 mg 
for the 25% vehicles. 
5.2.4.3. Comparison of Drug Candidates 
The three drug candidates which have been incorporated 
into the sustained release vehicle of Carbopol 934P, acacia, 
calcium diluent, and magnesium stearate were chosen based on 
their chemical and physical properties. These vehicles have 
displayed the ability to sustain the release of all three 
candidates but release profiles for each differ under specific 
given conditions. Figure 27 provides a direct comparison of 
drug release from vehicles containing 3% Carbopol 934P. The 
initial slope of the percent drug released versus the square 
root of time has been calculated and plotted as a function of 
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CHAPTER VI. Discussion 
The sustained delivery of drug candidates from solid 
dosage forms has become the focus of extensive research and 
development efforts in the pharmaceutical industry in recent 
years. The reasons for these efforts are many fold ranging 
from concerns for the efficiency of drug action to the role of 
patient compliance in dosage form administration. 
Most solid dosage forms are designed to dissolve and/or 
disintegrate upon immediate contact with the aqueous media of 
the gastrointestinal tract thus making their entire drug 
content available for absorption into the systemic 
circulation. This scenario of drug delivery produces an 
initial peak drug concentration in the bloodstream once the 
drug has entered the systemic circulation. A most desirable 
peak level would exist within the therapeutic window at a 
level sufficient to provide a pharmacological effect for a 
three to four hour period of time. The duration of drug 
action is dependent upon the peak level and the elimination 
kinetics of the particular drug candidate. Often times this 
peak concentration may exceed a level above which the patient 
will begin to experience side effects associated with the 
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higher than desirable levels. As the drug is eliminated from 
the body via various mechanisms such as filtration and 
enzymatic degradation its concentration will gradually 
decrease to a level below which pharmacological activity is 
diminished which is referred to as the minimum effective 
concentration (MEC) for that particular drug. At this point, 
in order to maintain pharmacological activity a maintenance 
dose must be administered to the patient. 
It would be desirable to maintain a more constant level 
of drug in the bloodstream to minimize the occurrence of side 
effects associated with the peak levels and to decrease the 
frequency of administration normally required to prolong 
pharmacological activity. One mechanism to maintaining a more 
constant level of drug in the body is through its sustained 
delivery over an extended period of time as opposed to its 
immediate release from conventional solid dosage forms. 
Advantages of this approach include an extended duration of 
pharmacological activity, a decrease in the occurrence of side 
effects, a decrease in the frequency of administration, and 
improvement of the efficiency with which existing drugs can be 
of benefit to the patient. Approaches taken in achieving 
sustained release of drug fall into three general categories 
including the physical design of the dosage form, modification 
of the drug molecule itself, and through formulation of the 
dosage form. 
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The focus of this doctoral dissertation is a novel 
approach to the formulation of sustained release solid dosage 
forms employing calcium sulfate dihydrate, dibasic calcium 
phosphate dihydrate, and tribasic calcium phosphate as matrix 
forming agents. 
6.1. Preliminary Studies 
Previous experience in formulation with the 
pharmaceutical diluents calcium sulfate dihydrate, dibasic 
calcium phosphate dihydrate, and tribasic calcium phosphate 
and a knowledge of their relatively low solubilities led to an 
investigation of their effect on release of medicament from 
solid dosage forms. 
Solubility profiles were generated for calcium sulfate 
dihydrate, dibasic calcium phosphate dihydrate, and tribasic 
calcium phosphate in media of pH 1.1, 4.0, 5.5, 6.5, and 7.5. 
The data (Figure 8, section 5.1.1.2.) indicate the highest 
solubility for each diluent to exist at a pH 1.1 with a 
decrease to practically insoluble levels at pH 7. 5. The model 
drug acetaminophen was chosen for this project due to its 
relatively pH independent solubility over the same pH range 
(Figure 9, section 5.1.1.2.). 
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Results (Figures 10, II, 12, section 5.1.3.) indicate a 
faster rate of medicament release at pH 1.1 for each of the 
three diluents. The rates of drug release exhibited by each 
formulation are inversely proportional to the solubility of 
the diluent employed at each pH. Most interesting is that the 
dosage forms tested in media of pH 4 • 0 to 7 • 5 remained 
practically intact throughout the testing period while 
releasing up to 35% of their drug contents from one exposed 
tablet surface. The data and the channel-like appearance of 
the surface of the dosage form suggest the existence of a 
matrix type delivery system. All data was initially reported 
on a percent released versus time basis. 
Drug dispersed throughout a solid matrix structure is 
released initially by dissolution from the immediate outer 
surface of the dosage form followed by leaching from its 
channel-like infrastructure via penetration of the surrounding 
aqueous media. The drug-solvent interface will recede into 
the inner portions of the matrix structure with time, 
therefore diffusion of the dissolved drug molecules from the 
matrix becomes an additional factor in its ultimate release. 
It was previously established that due to this diffusional 
process a linear relationship should exist between the amount 
of drug released and the square root of time (Higuchi). The 
drug release data from the studies described above was 
therefore subjected to a least squares linear regression 
analysis and plot of the line of best fit. 
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statistical 
results and least squares fit (Figures 13, 14, 15, section 
5.1.3.) indicate a strong linear relationship for the data at 
pH 4.0 to 7.5 with a direct correlation between the rate of 
drug release and the diluent solubility (Figure 8, section 
5.1.1.1.). Interestingly, these are the pH values at which 
the dosage forms remained intact which sUbstantiates the 
existence of a matrix type delivery system. Conversely, at a 
pH of 1.1 where the solubility of each diluent is highest and 
the dosage form does not remain intact the linear relationship 
is not as prevalent. 
6.2. Primary studies 
Results from these preliminary studies (Figures 13, 14, 
15, section 5.1.1.1.) of the effect of the insoluble diluents 
calcium sulfate dihydrate, dibasic calcium phosphate 
dihydrate, and tribasic calcium phosphate on medicament 
release from directly compressed solid dosage forms indicate 
that each diluent maintains a matrix structure during drug 
release in media of pH 4. 0 to 7. 5 . The data indicate that due 
to this matrix forming ability medicament release can be 
sustained over an eight to ten hour period. However, in the 
presence of O.1N HCl the calcium salts do not retain their 
matrix forming ability as a result of their higher 
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solubilities in such an environment (Table 1, Figure 8). 
Hence, a challenge to the employment of these diluents in the 
formulation of sustained release solid dosage forms for oral 
administration is their protection from the acidic environment 
of the gastric region. This will allow for the subsequent 
delivery of the dosage form into the more basic environment of 
the intestinal • regl.on. An apparent choice for such a 
protective mechanism would be an enteric coating process in 
which the coating material would provide a protective outer 
shell to the dosage form due to its acid insolubility. This 
material would begin to dissolve upon entry into the 
intestinal region where its solubility is higher, hence an 
exposure of the inner portion of the dosage form and 
initiation of medicament release. This appears to be a 
logical approach but difficulties often exist in the 
manufacture of enteric coated products including the 
uniformity of the applied coat, its stability, and its 
dependence on the physiological environment of each patient. 
wi th respect to the simple processing method used in the 
manufacture of the tablets in the preliminary studies an acid 
resistivity screening study was initiated. The purpose of 
this screening was to evaluate the effect of the incorporation 
of other pharmaceutical excipients on the behavior of the 
dosage form in the presence of O.IN He!. 
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6.2.1. Acid Resistivity 
Excipients selected as candidates for incorporation fall 
into three general categories. The first group included the 
natural gums; xanthan gum, guar gum, and gum arabic (acacia). 
The philosophy in selecting these excipients for evaluation 
was based upon past experience with their use as natural 
binders. Previous employment of acacia as a binding agent in 
a wet granulation with the more highly soluble diluent lactose 
yielded a dosage form which remained practically intact for an 
hour upon exposure to an aqueous environment. An awareness of 
these characteristics initiated the idea of their use to 
provide a more cohesive character to the dosage form and to 
increase the overall binding strength of the blend. The three 
excipients were tested by blending each with drug and calcium 
diluent, then compressing into a solid dosage form and placing 
in a beaker of O.1N Hel for observation overnight. Results 
(Table 6, Section 5.2.1.) indicate that tablets containing 
guar gum (5 & 15%) or xanthan (15%) with calcium sulfate 
dihydrate disintegrated in the presence of 0.1N Hel when left 
overnight. Conversely, the tablets containing acacia (10 & 
15%) with calcium sulfate dihydrate remained intact overnight. 
The second group of excipients included some enteric 
materials such as hydroxypropylmethylcellulose, cellulose 
acetate phthalate, cellulose acetate trimellitate, and 
hydoxypropylmethylcellulose phthalate 55. 
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These materials 
were included in the evaluation based on their natural acid 
insolubility and the expectation that their presence in the 
formulation would lend to the dosage form a more acid 
resistant nature. Results (Table 6, section 5.2.1.) indicate 
that the tablets containing these materials either capped, 
flaked, or chipped when introduced to O.1N Hel possibly due to 
their granular or needlelike shape. 
A third group of excipients tested were agents such as 
carbopol 934P which is carboxypolymethylene. Reasoning 
associated with the testing of this particular excipient was 
its gelling ability in the presence of O.1N Hel. The idea was 
if used in low concentrations the gel could provide a 
protective barrier to the dosage form without sacrificing the 
existence of the matrix structure. Results (Table 6, section 
5.2.1.) indicate that a dosage form containing Carbopol 934P 
(5 & 15%), calcium sulfate dihydrate, and the model drug 
acetaminophen existed as a continuous pasty mass upon exposure 
to O.1N Hel overnight. 
Both acacia and Carbopol 934P show promise in assisting 
a blend of calcium sulfate dihydrate and the model drug 
acetaminophen in the retention of its matrix structure in the 
presence of O. 1N HCI (Table 6, Section 5. 2 . 1. ) • Based on 
these observations, additional studies were initiated to 
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evaluate medicament release from directly compressed solid 
dosage forms containing each of these excipients, calcium 
sulfate dihydrate, and the model drug acetaminophen under less 
than favorable conditions. Release data (Table 7, section 
5.2.1.1.) indicate that the dosage form containing acacia (5 
& 25%) released 100% of its drug content via an erosion 
process in the presence of 0 . 1N HCl under the conditions 
outlined in Section 4.3.1. It was noted that the rate erosion 
in O.lN HCl was slowed to an even greater extent when the 
level of acacia was increased to 25%. Conversely, results 
(Table 8, section 5.2.1.1.) indicate that the dosage forms 
containing Carbopol 934P (5 & 15%) sustained the release of 
acetaminophen over a period of four hours. The 15% vehicle 
sustained medicament release to a greater degree than the 5% 
vehicle but its physical rigidity was less than that of the 5% 
vehicle. 
A common concern with the in vivo performance of 
sustained release solid dosage forms is their ability to 
withstand the rigors provided by their movement within the 
gastrointestinal tract following oral administration. A 
sustained release solid dosage form normally contains three to 
four times the amount of drug that a single immediate release 
dosage form contains, therefore, dose dumping due to 
mechanical failure becomes a concern. with respect to this 
our goal was to establish a sustained release vehicle with 
optimum physical stability whose 
predictable and reproducible. It 
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performance is both 
would appear from an 
examination of the data that the formulation containing 15% 
Carbopol 934P would be the most promising sustained release 
vehicle. However, the formation of a not so rigorous gel-like 
mass during release raises concern for its physical stability 
under less than favorable conditions. Therefore, knowing the 
probable dwell time of the dosage form in such an environment 
(pH ~ 1.1) in the gastrointestinal tract of less than two 
hours (Mojaverian) the 5% level becomes a more promising 
candidate. Although release form the 5% vehicle is faster it 
maintains a solid, more rigid matrix structure during release. 
This reasoning led to the selection of the vehicle containing 
5% Carbopol 934P as the most promising sustained release 
candidate due to its physical rigidity and durability relative 
to the 15% vehicle. 
In summary, both acacia (5 & 25%) and Carbopol 934P (5 & 
15%) have shown promise in assisting calcium sulfate dihydrate 
ad the model drug acetaminophen in maintaining a solid matrix 
structure in the presence of o. 1N HC1. The dosage form 
containing acacia only slowly eroded over a two hour period 
but yielded a very solid tablet following compression. 
Conversely, Carbopol 934P showed the ability when used in 
combination with calcium sulfate dihydrate to sustain 
medicament release over a four hour period in the presence of 
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O.lN HCI through a gelling effect which resulted in a loosely 
associated pasty mass. It seemed logical that if the 
properties of these two excipients could be simultaneously 
imparted on the dosage form containing calcium sulfate 
dihydrate and drug that a directly compressible sustained 
release vehicle could result. Therefore, studies to evaluate 
the use of a combination of acacia and Carbopol 934P in the 
formulation of this sustained release vehicle were initiated. 
studies were conducted to evaluate the release of the 
model drug acetaminophen from a vehicle containing Carbopol 
934P (1-5%), acacia (25%), and calcium sulfate dihydrate. 
Magnesium stearate was incorporated at a 0.5% level in all 
formulations to aid in the tableting process. The dosage 
forms were subjected to the conditions outlined in section 
4.4.2.2. which consisted of exposure to O.lN HCI for two hours 
followed by exposure to phosphate buffer (pH ~ 7.2) for the 
duration of the testing period. Results (Figure 16, Table 9, 
section 5. 2 • 1. 3 .) and observations indicate that indeed a 
dosage form results which not only remains intact upon initial 
exposure to O.lN HCI but also sustains medicament release over 
an eight hour period at a nearly constant rate. 
Interestingly, the tablet matrix remained practically intact 
throughout the testing period while releasing nearly all of 
its drug content suggesting the existence of a matrix type 
delivery system. 
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6.2.2. Processing variables 
The ability of Carbopol 934P, acacia, and calcium 
sulfate dihydrate to form a matrix type sustained release 
vehicle led to the investigation of the effect of several 
processing variables on the performance of the sustained 
release vehicle. In pharmaceutical development, large scale 
production of dosage forms extensive evaluation of the scale-
up of the processing of these dosage forms from small 
development scale to a larger production scale. The 
processing of solid dosage forms involves various mixing and 
compression procedures hence variables associated with these 
procedures are of concern in the pharmaceutical development 
process. 
All experimental tablets tested thus far were 
manufactured under the conditions outlined in section 4.3.1. 
which consisted of manually blending the excipients with a 
microspatula in a small weigh boat prior to compression. This 
is a very low intensity procedure and is not a practical 
method of processing solid dosage forms on a large scale. 
Therefore, a study was initiated to investigate the effect of 
the intensity of the mixing episode on the performance of the 
sustained release vehicle. 
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Tablets containing Carbopol 934P (1 - 5%), acacia (25%), 
calcium sulfate dihydrate, magnesium stearate, and the model 
drug acetaminophen were manufactured under the condi tions 
outlined in section 4.3.2. by both the manual and v-blending 
methods. Drug release profiles were generated for each of the 
vehicles and results (Table 11, section 5.2.2.1.) indicate 
that the more intensely mixed v-blend exhibits a release 
profile that is sustained to a greater degree. This is 
possibly due to the dispersion of the excipients, chemical 
and/or physical interaction of the excipients, or physical 
occlusion or entrapment of the drug molecules by the 
excipients. The exact cause of this decrease in release rate 
is beyond the scope of this study but may be addressed in 
subsequent studies. 
An extended study was conducted to evaluate the effect of 
the duration of mixing on the performance of the sustained 
release vehicle. Interestingly, it was noted that virtually 
no differences exist in release of medicament from dosage 
forms blended for 5, 20, and 45 minutes (Table 10, stat. 
Appendix, section 5. 2 • 2 • 1. ) . A two sample analysis of 
variance was performed to statistically compare the percent 
drug released form each blend following 60 and 480 min of 
testing. These times were chosen as representatives of 
initial and terminal drug release and the data reveals almost 
identical average values for each sample set (Statistical 
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Appendix, Mixing Time Section). statistical comparison of 
these release profiles also indicated that there was no 
statistically significant difference in medicament release 
from these vehicles. 
The establishment of the vehicle as a matrix type drug 
delivery system warranted an investigation of the effect of 
compression force employed in tablet manufacture on the 
release of medicament. Due to the channel-like network of the 
tablet infrastructure the effect of the force applied to the 
blend during compression is an obvious concern. Results 
(Figure 17, section 5.2.2.2.) indicate that dosage forms 
subjected to compression forces of 4000 and 6000 lbs show no 
statistically significant difference in their rates of 
medicament release. Possible reasons for such findings may 
involve the exceeding of the limit of compressibility of the 
diluents and hence similar matrix characteristics regardless 
of the compression force applied. Whatever the reasons, these 
findings are positive from a production perspective in that a 
range of compression forces has been established which can be 
applied in the manufacture of the dosage form within which the 
release characteristics will not be appreciably altered. 
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6.2.3. Formulation Variables 
Initial screening and medicament release studies 
established the ability of a vehicle consisting of 5% Carbopol 
934P, 25% acacia, calcium sulfate dihydrate, and 0.5% 
magnesium stearate to sustain the release of the model drug 
acetaminophen over a 10 hr period. Each excipient plays a 
vi tal role in the performance of this sustained release 
vehicle. Carbopol 934P functions to provide a protective gel-
like barrier about the exterior of the dosage form in the 
presence of 0.1~ HCl and acacia exerts a binding effect to 
assist in the retention of a solid matrix structure throughout 
the release period. Calcium sulfate dihydrate provides the 
matrix network due to its insoluble character and ability to 
form a solid matrix upon direct compression. Magnesium 
stearate functions to aid in the tableting process through its 
lubricating capabilities thus preventing sticking within the 
die cavity and on punch face surfaces during the compression 
cycle. Due to the specific roles which each of these 
excipients play in the performance of this vehicle it is 
paramount to understand the effect of changes in each 
parameter. Therefore, studies were performed to evaluate the 
effect of altering the levels of Carbopol 934P, acacia, and 
the type of diluent employed on the performance of this 
sustained release vehicle. 
147 
Results (Table 8) indicate that due to the gelling 
character of Carbopol 934P its functions to form a gel-like 
barrier about the exterior of the dosage form in the presence 
of .1N HCl while simultaneously assisting in sustaining the 
release of the model drug acetaminophen. An investigation of 
the effect of the level of Carbopol 934P employed in this 
vehicle was conducted with dosage forms containing 0, 1, 3, 
and 5% Carbopal 934P manufactured as outlined in section 
4.3.2. The tablets were subjected in duplicate to the testing 
protocol outlined in section 4.4.2. 
Results (Table 12, section 5.2.3.1.) indicate that as the 
percent of Carbopol 934P is increased the rate of medicament 
release is decreased. The vehicle containing no Carbopol 
began to erode immediately upon exposure to 0.1N HCl while 
releasing 43% of its drug content in the initial hour of 
testing and greater than 90% in four hours. Conversely, the 
1, 3, and 5% vehicles exhibited visually detectable 
differences in the degree of gelling on their exterior 
surfaces while releasing 26.45%, 22.25%, and 13.70% of their 
drug contents in the initial hour of testing. These same 
vehicles released 84.80, 80.80, and 43.15% of their drug 
contents throughout the ten hour testing period with no signs 
of the termination of release when sampling was discontinued. 
The dosage forms exhibited different degrees of erosion during 
testing with the 0% vehicle totally eroding, the 1% vehicle 
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yielding a small solid mass, the 3% vehicle a slightly larger 
mass, and the 5% vehicle a solid mass possessing nearly the 
same physical dimensions of the dosage form prior to testing. 
The differences in the release profiles are easily 
understood with inspection of the dosage forms throughout the 
release period. comparison of the release of drug from the 0% 
vehicle with that of the 1% vehicle reveals the importance of 
the presence of Carbopol 934P to the ultimate performance of 
this vehicle. The gelling effect provided by the Carbopol 
934P is paramount in the protection of the dosage form in the 
presence of O.lN HCl and throughout the release process. In 
the absence of Carbopol 934P the O.IN HCl and the agitating 
action of the turning basket are free to directly contact and 
dissolve the calcium diluent matrix causing a rapid release of 
medicament over a three hour period as opposed to a sustained 
release profile over 10 hr in the presence of O.IN HCl. These 
results (Table 12, Figure 18 and 19, section 5.2.3.1.) further 
sUbstantiate the importance of the role of the Carbopol 934P 
in the sustained release capabilities of this vehicle. The 
correlation of the percent Carbopol 934P with the degree of 
erosion exhibited by each dosage form during testing also 
establishes the role of this gelling agent in the protection 
of the vehicle during exposure to O.lN Hel and ultimately its 
role in retaining the calcium sulfate dihydrate matrix. The 
ability to alter the rate of drug release via adjustment of 
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the level of Carbopol 934P is important in allowing 
cllstomization of medicament release based on drug solubility 
and the desired release profile. This will be elaborated upon 
in subsequent sections in discussion of the delivery of other 
drug candidates from this vehicle. 
Higuchi et al have described drug release from a matrix 
type delivery system and the linear relationship between the 
amount of drug released and the square root of time. This 
relationship exists as a result of the continuous leaching of 
drug from the matrix system by virtue of the penetration of 
the release medium and the subsequent recession of the drug 
solvent interface with time. Due to the inward movement of 
this interface, once the drug has entered solution it must 
diffuse through the vacated channels and pores of the matrix 
infrastructure before it is ultimately released from the 
dosage form hence the existence of this linear relationship. 
The system under investigation has exhibited matrix 
forming and release capabilities therefore a least squares 
linear regression analysis of the percent drug released on the 
square root of time was performed. The regression statistics 
reveal a strong relationship at Carbopol levels of 1, 3, and 
5% (Table 12 , Figure 19, section 5. 2 • 3 . 1. ) all of which 
maintained a solid matrix structure throughout the release 
period. However, the 0% Carbopol 934P vehicle which eroded 
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during release due to the absence of gelling capability and no 
protective barrier showed a much weaker linear relationship 
between the percent drug released and the square root of time. 
Likewise, studies were conducted to evaluate the effect 
of the level of acacia employed in the sustained release 
vehicle containing Carbopol 934P (5%), calcium sulfate 
dihydrate, and magnesium stearate. Dosage forms containing 
15,20, and 25% acacia were manufactured and tested as 
outlined in section 4.3.2.2. and 4.4.2. 
Results (Table 13, Figure 20, Section 5.2.3.2.) and 
statistical analysis indicate no statistically significant 
differences in the amount of drug released from the 15 and 20% 
vehicles in the first hour or throughout the entire testing 
period. However, comparison of the 15 and 20% vehicles with 
the 25% vehicle indicate statistically significant differences 
in release over the ten hour period with 83.16, 81.20, and 
43.15% drug released, respectively. Inspection of the dosage 
forms post testing reveals a larger degree of erosion with the 
15 and 20% vehicle as compared to very little erosion with the 
25% vehicle. This is readily understood when correlated with 
the amount and rate of drug release from the different 
formulations. Special note should be made of the drastic 
decrease in rate of medicament release when the level of 
acacia is increased to a 25% level. No concrete explanation 
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is readily available for this occurrence but it is apparent 
that at some point between 20 and 25% acacia levels a change 
in the vehicle occurs due to the rigidity of the matrix 
structure of the character of the Carbopol 934P/acacia 
combination. This occurrence has been investigated but no 
conclusi ve evidence exists to support the data and thus 
additional investigation is warranted. 
A least squares linear regression analysis of the percent 
drug released versus the square root of time indicates a 
linear relationship at all three levels of acacia. The 
results of these analyses coupled with the observations of the 
ability of these vehicles to remain intact throughout a 10 to 
12 hr testing period while releasing most of their drug 
content sUbstantiates the existence of a nondisintegrating, 
matrix drug delivery system. 
Dibasic calcium phosphate dihydrate showed similar matrix 
forming abilities to calcium sulfate dihydrate in preliminary 
studies and thus warranted evaluation of its incorporation 
into this sustained release formulation. Percent drug 
released data (Table 14, section 5.2.3.3.) indicate the 
ability of dibasic calcium phosphate dihydrate to sustain the 
release of the model drug acetaminophen over an extended 
period of time when formulated with Carbopol 934P (5%), acacia 
(25%), and magnesium stearate. 
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statistical analysis shows that the vehicle performs in 
a reproducible fashion (Table 14) and drug release exhibits a 
linear relationship with the square root of time suggesting 
the existence of a matrix drug delivery system. However, 
observation of the dosage form during testing reveals the 
existence of a gel-like mass which slowly erodes during 
release. When 1 and 3% levels of Carbopol 934P are employed 
release is much faster and the linear relationship between 
percent drug released and the square root of time is not as 
evident. These results indicate that dibasic calcium 
phosphate dihydrate holds promise as a matrix forming agent in 
the formulation of sustained release solid dosage forms but 
release from such a vehicle appears to occur via an erosion 
process rather than the diffusional process observed with 
calcium sulfate dihydrate as diluent. 
A direct comparison of the best fit regression plots and 
the statistics (Tables 12 and 15, Figures 20 and 22) from the 
vehicles containing calcium sulfate dihydrate and dibasic 
calcium phosphate dihydrate reveal the difference in the 
physical existence of their matrices. The calcium sulfate 
dihydrate vehicle exhibits a strong linear relationship 
between the percent drug released and the square root of time 
with the best fit plots of the 1, 3, and 5% vehicles 
intersecting the y-axis very near the origin. These results 
coupled with the existence of a solid mass throughout the 
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release period sUbstantiate the existence of a solid matrix 
drug delivery system. Conversely, the statistics and linear 
regression analyses from the dibasic calcium phosphate 
dihydrate vehicle display a linear relationship between the 
percent drug released and the square root of time for all 
three levels of Carbopol 934P. However, examination of the 
best fit plots reveals that the 1 and 3% data intersect the y-
axis at ~ 10 and 40% drug released whereas the 5% vehicle data 
intersects near the origin. These findings coupled with the 
existence of a gel like continuous mass during release 
identifies the existence of a more loosely defined matrix than 
with the calcium sulfate dihydrate vehicle. 
Likewise, tribasic calcium phosphate showed similar 
matrix forming abilities in preliminary studies and was 
therefore evaluated for incorporation into the sustained 
release vehicle. Results (Table 16, section 5.2.3.4.) 
indicate that such a vehicle erodes and ultimately 
disintegrates over a five hour period and hence is not as 
promising as a matrix forming agent. It should also be noted 
that problems with capping and sticking of the dosage form 
during compression in preparation for the preliminary studies 
contributed to the selection of the other calcium diluents for 
more detailed evaluation in the primary studies. 
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6.2.4. Other Drug Candidates 
The testing of the release characteristics of the model 
drug acetaminophen from a vehicle containing Carbopol 934P, 
acacia, calcium diluent, and magnesium stearate allowed for 
the evaluation of the effect of various formulation and 
production variables on the performance of the vehicle. 
However, it is evident that due to its high dose nature 
acetaminophen is not a therapeutically practical sustained 
release candidate, therefore, tests were initiated to evaluate 
the release of more practical drug candidates from this 
sustained release vehicle. 
Theophylline possesses a solubility of ~ 10 mg/ml in O.lN 
Hel and its incorporation allows for the evaluation of the 
release of a practical sustained release candidate from a 
vehicle of Carbopol 934P, acacia, calcium sulfate dihydrate, 
and magnesium stearate. Theophylline release profiles were 
initially generated from two different formulations containing 
5% Carbopol 934P, 25% acacia, 0.5% magnesium stearate, and 
either calcium sulfate dihydrate or dibasic calcium phosphate 
dihydrate. Results (Table 17, Figure 22, Section 5.2.4.1.) 
indicate that drug release from both vehicles is sustained 
over a 10 hr period. The vehicle containing calcium sulfate 
dihydrate as diluent released an average of 62.53% with an 
average of 93.65% release from those formulations containing 
dibasic calcium phosphate dihydrate. 
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All tablets had an 
initial weight of 400 mg and an examination of the dosage 
forms during and after testing reveals the mechanism by which 
drug release occurs. The three tablets containing calcium 
sulfate dihydrate remained practically intact with final 
weights of 212, 229, and 216 mg which is indicative of matrix 
diffusional release. Conversely, those containing dibasic 
calcium phosphate dihydrate eroded slowly throughout the 
testing period. An explanation of the behavior exhibited by 
these two formulations may lie in a review of the solubility 
and tableting characteristics of the two calcium diluents. 
Calcium sulfate dihydrate which possesses the lowest 
solubility in O.IN Hel produces an extremely hard mass when 
compressed remains intact during release whereas dibasic 
calcium phosphate dihydrate whose solubility is twice that of 
calcium sulfate dihydrate in o. IN Hel slowly erodes throughout 
the release period. Only 62.53% drug is released from the 
solid matrix in 10 hr but there was no indication of the 
termination of release suggesting a continuous leaching of 
drug. The erodable matrix which released nearly all of its 
drug content in the same period of time would appear to be the 
more desirable dosage form from a therapeutical perspective 
yet its susceptibility to structural failure is a concern. 
These observations and results raise the question of the 
feasibility of the use of a combination of the two diluents to 
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provide a physically stable matrix delivery system which is 
also capable of delivering nearly all of its drug content over 
a 10 to 12 hr period. It was evident that theophylline 
release was affected to a lesser degree with changes in the 
level of Carbopol 934P, acacia, or the type of calcium diluent 
employed than was acetaminophen possibly due to its lower 
solubility in O.IN HCl. A discussion of the role of drug 
solubility in release will be presented in a later section. 
The complimentary roles of Carbopol 934P and acacia was 
evident in a study conducted which evaluated the release of 
theophylline from three different vehicles. All three 
vehicles contained theophylline, calcium sulfate dihydrate, 
and magnesium stearate with one containing no Carbopol 934P 
and 25% acacia, the second with 5% Carbopol 934P, and a third 
with 5% Carbopol 934P and 10% acacia. Results (Table 19, 
Figure 24, section 5.2.4.1.) indicate a 100% release of drug 
in two to three hours in the absence of either Carbopol 934P 
or acacia with only a 68% release in ten hours with the 5% 
Carbopol 934P/10% acacia combination. These results 
sUbstantiate the importance of the combination of these two 
excipients to the sustained release capabilities of this 
vehicle. 
Evaluation of the release of the highly soluble 
chlorpheniramine maleate (~ 50 mg/ml) was a true test of the 
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sustained release vehicle. Results (Section 5.2.4.2.) 
indicate that it is indeed capable of sustaining the release 
of this commonly used antihistamine over a 12 hr period. 
However, due to the high solubility of the drug candidate 
initial release was much faster in the presence of O.lN HCI 
than in the pH 7.2 buffer. This type of release profile 
exhibits a burst effect which may be advantageous in elevating 
blood drug levels to therapeutically desirable levels soon 
after administration. This will not be evident until in vivo 
tests can be performed and therefore is beyond the scope of 
this research project. It is evident that medicament release 
profiles can be predictably altered by changing the level of 
Carbopol 934P or acacia employed in the formulation. 
6.2.5. Comparison of Drug Candidates 
Acetaminophen was employed as a model drug for the 
initial evaluations of the performance of the sustained 
release vehicle discussed here to eliminate drug solubility as 
a variable in determinations of drug release profiles. 
Although not a practical sustained release candidate due to 
its high dose nature acetaminophen does provide an indication 
of the behavior of drugs which may fall into the same 
solubility range. These are the reasons for the additional 
investigations of the more practical sustained release drug 
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candidates theophylline and chlorpheniramine maleate. 
Theophylline possesses a lower solubility of ~ 10 mg/ml in 
O.IN HCl than acetaminophen (23 mg/ml) and therefore provides 
an indication of the release of a relatively low solubility 
drug candidate from the vehicle of interest. Conversely, 
chlorpheniramine maleate provides an indication of the release 
of a more freely soluble (~ 50 mg/ml) drug from the vehicle 
and is an ultimate test of the ability of the vehicle to 
sustain the release of a drug that should be difficult to 
control. The inclusion of all three drug candidates provides 
an indication of the ability of this vehicle to sustain the 
release of drugs possessing a broad range of solubilities. 
The ability to sustain the release of drug upon initial 
exposure to O.IN HC! is a primary concern in the performance 
of sustained release vehicles for oral administration. The 
sustained release vehicle presented here demonstrates this 
ability and therefore a comparison of the initial release 
profiles of the three drug candidates was conducted. Drug 
release from such a matrix system occurs through the initial 
dissolution of drug deposited on the outer surfaces of the 
matrix followed by leaching of the drug from the channel-like 
infrastructure of the matrix via penetration of the aqueous 
media. Comparison (Figures 27, 28, 29, section 5.2.4.3.) of 
drug release rates from vehicles containing the three drug 
candidates shows a direct relationship between the solubility 
of the drug in O.1N HCl and the initial rate of release from 
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the given vehicle. This comparison indicates not only the 
ability of the vehicle to sustain the release of various drug 
candidates but also the ability to control drug release rates 
through adjustment of formulation parameters. 
6.2.6. Summary 
Results from this research have established the ability 
of a vehicle containing Carbopol 934P (1 - 5%), acacia (10 -
25%), calcium diluent, and magnesium stearate (0.5%) to 
sustain the release of three different drug candidates. This 
approach is novel in that it involves only the blending of the 
excipients and drug followed by direct compression into a 
solid dosage form. This sustained release vehicle has also 
exhibited the ability to perform in a reproducible fashion 
with release profiles being controlled by two formulation 
parameters. 
The performance of the vehicle appears to be unaffected 
by changes in processing variables such as mixing time and 
compression force employed during tablet manufacture. There 
is no guarantee that changes will not occur in the scale up to 
production sized batches but from a pharmaceutical development 
perspective initial findings are encouraging. 
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with the astronomical costs currently associated with the 
development of novel drug delivery systems there are always 
needs for novel, simple approaches to pharmaceutical product 
development and production. An alternative approach to the 
formulation of sustained release solid dosage forms has been 
presented here which promises to be simple while retaining 
product reproducibility and predictability. 
The execution of the study involved the evaluation of 
release of three different drug candidates possessing a broad 
range of solubilities from the same formulation employing 
calcium diluents as matrix forming agents. The vehicle 
displayed the ability to sustain the release of all three drug 
candidates in a reproducible fashion and flexibility in 
altering the rate of medicament release through adjustment of 
two formulation parameters. The initial release studies 
employed the model drug acetaminophen at a 20% loading due to 
its chemical and physical characteristics with additional 
employment of theophylline (25%) and chlorpheniramine maleate 
(2.5%) at therapeutically practical levels. The ability of 
this vehicle to sustain the release of this broad range of 
drug loading levels further sUbstantiates its application as 
a feasible drug delivery system. 
The employment of these calcium diluents as matrix 
forming agents in the formulation of sustained release solid 
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dosage forms is a novel approach and has only been briefly 
introduced in this doctoral dissertation. Much investigation 
remains to be performed in the true validation of their use in 
such a capacity but preliminary findings have provided endless 
avenues for study. 
As investigational research should, these findings have 
initiated numerous ideas for additional investigation of the 
applicability of this approach to the formulation of sustained 
release solid dosage forms. It is evident that its 
application to other drug candidates must be evaluated on an 
industrial basis but preliminary findings have been promising. 
studies must also be conducted to evaluate the amenability of 
these formulations to mass production. For instance, can 
these excipients be subjected to a dry or wet granulation 
procedure and still maintain their sustained release 
characteristics. Some additional characterization of the 
mechanics of drug release and matrix infrastructure must be 
conducted but is beyond the scope of this project. Ultimate 
challenges to sustained release technology lie in the control 
of the release of highly soluble drugs hence the feasibility 
of employing the technique presented here to achieve this is 
of paramount interest. Endless possibilities exist for 
investigation but probably the most interesting aspect 
presented here is a process which could be relatively 
inexpensive yet whose performance is reproducible. The 
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astronomical costs associated with pharmaceutical development 
are always a concern and are reflected in the spiralling costs 
of commercially available medications. 
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STATISTICAL APPENDICES 















4000 lbs compression force 
statistical Parameters: 
Mixing Time (min) 
5 min 20 min 
No. of CbS. 2 2 
Averaqe 14.25 14.25 
variance 0.125 0.125 
std. Deviation 0.353 0.353 
Median 14.25 14.25 
Hypothesis Test for Ho: Diff = 0 
vs Alt: NE 
at Alpha = 0.05 























comment: At a 95% confidence level there is no statistically 
significant difference in the percent drug released from the 
three vehicles mixed for 5 I 20 I and 45 minutes I 
respectively. 
Conditions: 480 minute data 
4000 lbs compression force 
statistical Parameters: 
Mixing Time (min) 
5 min 20 min 
No. of Obs. 2 2 
Averaqe 44.35 44.75 
Variance 3.125 0.125 
std. Deviation 1.767 0.353 
Median 44.35 44.75 
Hypothesis Test for Ho: Diff = 0 
vs Alt: NE 
at Alpha = 0.05 























comments: At a 95% confidence level there is no significant 
difference in the percent drug released from the vehicle mixed 
for 5, 20, and 45 minutes, respectively. 















4000 Ibs compression force 



















Hypothesis Test for Ho: Diff = 0 
vs Alt: NE 
at Alpha = 0.05 









comments: At a 95% confidence level there is a statistically 
siqnificant difference in the percent drug released from the 
vehicles blended by manual technique and that in the v-
blender. 













qs to 400 mg 
0.5 
Conditions: 60 minute sample 
4000 Ibs compression force 
























Hypothesis Test for Ho: niff = 0 
vs Alt: NE 
Computed t stat 
siqnificance Level 
Conclusion 




















Comments: At a 95% confidence level there is no statistically 
significant difference in the percent drug released from the 
two vehicles containing 1 and 3 % Carbopol , respectively. 
However, there is a statistically siqnificant difference in 
the percent drug released from the vehicles containing no 
Carbopol 934P and 1% Carbopol 934P. There is also a 
statistically siqnificant difference in the percent drug 
released from the vehicle containing 3% Carbopol 934P and 5% 
Carbopol 934P. 
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conditions: 600 minute sample 
4000 lbs compression force 
Level 
O~ 1~ 
No. of Oba. 2 2 
Averaqe 100.35 84.8 
Variance 3.64 15.68 
std. Deviation 1.91 3.96 
Median 100.35 84.8 
Hypothesis Test for Ho: Diff = 0 
vs Alt: NE 
at Alpha = 0.05 






















comments: At a 95% confidence level there is no 
statistically aiqnificant difference in the percent drug 
released from the the vehicles containing 1 and 3% Carbopol 
934P, respectively. However, there is a statistically 
siqnificant difference in the percent drug released from the 
vehicles containing no Carbopol and 1% Carbopol. There is 
also a statistically siqnificant difference in the percent 
drug released for the vehicles containing 3 and 5% Carbopol. 













qs to 400 mg 
0.5 
4000 Ibs compression force 
Levels of Acacia 
15% 
No. of Cbs. 3 
Average 22.70 
variance 0.16 
std. Deviation 0.40 
Median 22.70 
Hypothesis Test for Ho: Diff = 0 
vs Alt: NE 








Computed t stat 
Significance Level 
Conclusion 
15/20 
0.79 
0.47 
dnr Ho 
15/25 
24.03 
.0001 
REJECT Ho 
25% 
2 
14.25 
0.12 
0.35 
14.25 
20/25 
9.44 
.0025 
REJECT Ho 
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